University of Central Florida

STARS
UCF Patents

Technology Transfer

5-26-2015

Methods and Compositions Comprising a C-Terminal Bax Peptide
(US)
Annette Khaled
University of Central Florida

Rebecca Boohaker
University of Central Florida

Michael Lee
University of Central Florida

J. Manuel Perez Figueroa
University of Central Florida

Find similar works at: https://stars.library.ucf.edu/patents
University of Central Florida Libraries http://library.ucf.edu
This Patent is brought to you for free and open access by the Technology Transfer at STARS. It has been accepted for
inclusion in UCF Patents by an authorized administrator of STARS. For more information, please contact
STARS@ucf.edu.

Recommended Citation
Khaled, Annette; Boohaker, Rebecca; Lee, Michael; and Perez Figueroa, J. Manuel, "Methods and
Compositions Comprising a C-Terminal Bax Peptide (US)" (2015). UCF Patents. 364.
https://stars.library.ucf.edu/patents/364

Illlll llllllll Ill lllll lllll lllll lllll lllll 111111111111111111111111111111111
US009040662B2

c12)

(54)

(75)

United States Patent

(10)

Khaled et al.

(45)

METHODS AND COMPOSITIONS
COMPRISING AC-TERMINAL BAX PEPTIDE
Inventors: Annette Khaled, Orlando, FL (US);
Rebecca Boohaker, Orlando, FL (US);
Michael Lee, Orlando, FL (US); Jesus
Perez Figueroa, Orlando, FL (US)

(73)

Assignee: UNIVERSITY OF CENTRAL
FLORIDA RESEARCH
FOUNDATION, Orlando, FL (US)

( *)

Notice:

(21)

Appl. No.:

14/240,801

(22)

PCT Filed:

Aug.24,2012

(86)

PCT No.:

PCT/US2012/052354

§ 371 (c)(l),
(2), (4) Date:

Feb.25,2014

(87)

Subject to any disclaimer, the term ofthis
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

PCT Pub. No.: W02013/029011
PCT Pub. Date: Feb. 28, 2013

Prior Publication Data

(65)

US 2014/0255299 Al

Sep. 11, 2014

Related U.S. Application Data
(60)

Provisional application No. 61/527,524, filed on Aug.
25, 2011, provisional application No. 61/645,891,
filed on May 11, 2012.

(51)

Int. Cl.
C07K 7108
A61K 38116
A61P35/00
A61K 38117
A61K 45106
A61K 9151

(52)

( 58)

(2006.01)
(2006.01)
(2006.01)
(2006.01)
(2006.01)
(2006.01)

U.S. Cl.
CPC ............... C07K 7108 (2013.01); A61K 3811761
(2013.01); A61K 915153 (2013.01); A61K 38116
(2013.01); A61K 45106 (2013.01)
Field of Classification Search
None
See application file for complete search history.
References Cited
U.S. PATENT DOCUMENTS

2002/0052316
2003/0096367
2004/0191843
2010/0099742
2014/0255299

Al
Al
Al
Al
Al

512002 Shore et al.
5/2003 Korsmeyer
912004 Wright et al.
412010 Stassi et al.
912014 Khaled et al.

US 9,040,662 B2
May 26, 2015

FOREIGN PATENT DOCUMENTS
CA
EP
WO
WO

2846629
2747773
W0-2013/029011
W0-2013/086430

Al
A2
A2
Al

2/2013
7/2014
2/2013
6/2013

OTHER PUBLICATIONS
U.S. Appl. No. 14/363,793, filed Jun. 7, 2014, Khaled.
Antonsson, B., et al. "Bax is present as a high molecular weight
oligomer/complex in the mitochondrial membrane of apoptotic
cells." J. Biol. Chem., vol. 276, pp. 1161511623 (2001).
Ausili, A., et al. "The interaction of the bax c-terminal domain with
negatively charged lipids modifies the secondary structure and
changes its way of insertion into membranes." J. Struct. Biol., vol.
164, pp. 146 (2008).
Barash, S., et al. "Human secretory signal peptide description by
hidden markov model and generation of a strong artificial signal
peptide for secreted protein expression." Biochem. Biophys. Res.
Commun., vol. 463, pp. 835-842 (2002).
Basanez, G., et al. "Bax-type apoptotic proteins porate pure lipid
bilayers through a mechanism sensitive to intrinsic monolayer curvature." J. Biol. Chem., vol. 277, pp. 49360 (2002).
Boohaker, R.J., et al. "Bax supports the mitochondrial network, promoting bioenergetics in nonapoptotic cells." Am. J. Physiol. Cell
Physiol., vol. 300, pp. Cl466-Cl478 (2011).
Brustovetsky, T., et al. "Bax insertion, oligomerization, and outer
membrane permeabilization in brain mitochondria: role of permeability transition and SH-redox regulation." Biochim. Biophys. Acta.,
vol. 1797, pp. 1795-1806 (2010).
Cartron, P.F. et al. "The first alpha helix ofbax plays a necessary role
in its ligand-induced activation by the BH3-only proteins bid and
puma." Mo!. Cell, vol. 16(5), pp. 807-818 (2004).
Cartron, P.F., et al. "Distinct domains control the addressing and the
insertion of bax into mitochondria." J. Biol. Chem., vol. 280, pp.
10587-10598 (2005).
Cartron, P.F., et al. "The expression of a new variant of the proapoptotic molecule bax, baxpsi, is correlated with an increased survival of glioblastoma multiforme patients." Hum. Mo!. Genet., vol.
11, pp. 675 (2002).
Cartron, P.F., et al. "The n-terminal end of bax contains a
mitochondrial-targeting signal." J. Biol. Chem., vol. 278, pp. 11633
(2003).
Deng, J., et al. "BH3 profiling identifies three distinct classes of
apoptotic blocks to predict response to ABT-737 and conventional
chemotherapeutic agents." Cancer Cell, vol. 12, pp. 171 (2007).
Er, E., et al. "Control of bax homodimerization by its carboxyl
terminus." J. Biol. Chem., vol. 282, pp. 24938 (2007).
Eskes, R., et al. "Bax-induced cytochrome c release from
mitochondria is independent of the permeability transition pore but
highly dependent on mg2+ ions." J. Cell Biol., vol. 143, pp. 217-224
(1998).
Garcia-Saez, A.J., et al. "Membrane-insertion fragments of bcl-xl,
bax, and bid." Biochemistry, vol. 43, pp. 10930 (2004).

(Continued)
Primary Examiner - Julie Ha
Assistant Examiner - Li Ni Komatsu
(74) Attorney, Agent, or Firm - Ballard Spahr LLP
(57)

(56)

Patent No.:
Date of Patent:

ABSTRACT

In an aspect, the invention relates to compositions and methods for permeabilizing membranes of cells. In an aspect, the
invention relates to compositions and methods for killing
cells. In an aspect, the invention relates to compositions and
methods of permeabilizing the membranes of cancer cells or
microbial cells.

18 Claims, 23 Drawing Sheets

US 9,040,662 B2
Page 2
(56)

References Cited

OTHER PUBLICATIONS
Garcia-Saez, A.J., et al. "Peptides corresponding to helices 5 and 6 of
bax can independently form large lipid pores." FEBS J., vol. 273, pp.
971 (2006).
Garcia-Saez, A.J., et al. "Peptides derived from apoptotic bax and bid
reproduce the poration activity of the parent full-length proteins."
Biophys. J., vol. 88, pp. 3976 (2005).
Garcia-Saez, A.J., et al. "Permeabilization of the outer mitochondrial
membrane by bcl-2 proteins." Adv. Exp. Med. Biol., vol. 677, pp.
91-105 (2010).
Gavathiotis, E., et al. "Bax activation is initiated at a novel interaction
site." Nature, vol. 455(7216), pp. 1076-1081 (2008).
Geisse, S., et al. "Recombinant protein production by transient gene
transfer into manunalian cells." Methods Enzymol., vol. 463, pp.
223-238 (2009).
George, N.M., et al. "Bax contains two functional mitochondrial
targeting sequences and translocates to mitochondria in a
conformational change- and homo-oligomerization-driven process."
J. Biol. Chem., vol. 285, pp. 1384 (2010).
Ghibelli, L., et al. "Multistep and multitask bax activation."
Mitochondrion, vol. 10, pp. 604-613 (2010).
Han, S-X, et al. "Secretory transactivating transcription-apoptin
fusion protein induces apoptosis in hepatocellular carcinoma hepg2
cells." World Journal of Gastroenterology, vol. 14(23), pp. 36423649 (2008).
Rorie, C., et al. "Characterization of signal that directs c-tail-anchored proteins to manunalian mitochondrial outer membrane." Mo!.
Biol. Cell, vol. 13, pp. 1615 (2002).
Kaufmann, T., et al. "Characterization of the signal that directs bclx(l), but not bcl-2, to the mitochondrial outer membrane." J. Cell
Biol., vol. 160, pp. 53-64 (2003).
Kelekar, A., et al. "Bcl-2-family proteins: the role of the bh3 domain
in apoptosis." Trends Cell Biol., vol. 8(8), pp. 324-330 (1998).
Leber, B., et al. "Embedded together: the life and death consequences
of interaction of the bcl-2 family with membranes." Apoptosis, vol.
12, pp. 897-911 (2007).
de! Martinez-Senac, M., et al. "Conformation of the c-terminal
domain of the pro-apoptotic protein bax and mutants and its interaction with membranes." Biochemistry, vol. 40, pp. 9983 (2001 ).
Nechushtan, A., et al. "Conformation of the bax c-terminus regulates
subcellular location and cell death." EMBO J., vol. 18, pp. 2330
(1999).
Oltersdorf, T., et al. "An inhibitor of bcl-2 family proteins induces
regression of solid tumours." Nature, vol. 435, pp. 677 (2005).
Oltvai, Z.N., et al. "Bcl-2 heterodimerizes in vivo with a conserved
homo log, bax, that accelerates progranuned cell death." Cell, vol. 74,
pp. 609-619 (1993).
Putcha, G.V., et al. "Bax translocation is a critical event in neuronal
apoptosis: regulation by neuroprotectants, BCL-2, and caspases." J.
Neurosci., vol. 19, pp. 7476-7485 (1999).
Robertson, J.D., et al. "Outer mitochondrial membrane
permeabilization: an open-and-shut case?" Cell Death Differ., vol.
10, pp. 485-487 (2003).

Roucou, X., et al. "Bax oligomerization in mitochondrial membranes
requires tbid (caspase-8-cleaved bid) and a mitochondrial protein."
Biochem. J., vol. 368, pp. 915-921 (2002).
Santra, S., et al. "Aliphatic hyperbranched polyester: a new building
block in the construction of multifunctional nanoparticles and
nanocomposites." Langmuir, vol. 26, pp. 5364 (2010).
Schinzel, A., et al. "Conformational control ofbax localization and
apoptotic activitybyprol68." J. Cell Biol., vol. 164, pp. 1021 (2004).
Schlesinger, P.H., et al. "The bax pore in liposomes." Biophysics,
Cell Death Differ., vol. 13, pp. 1403 (2006).
Suzuki, M., et al. "Structure ofbax: coregulation of dimer formation
and intracellular localization." cell, vol. 103, pp. 645-654 (2000).
Tait, S.W., et al. "Mitochondria and cell death: outer membrane
permeabilization and beyond." Nat. Rev. Mo!. Cell. Biol., vol. 11, pp.
621-632 (2010).
Valero, J.G., et al. "Bax-derived membrane-active peptides act as
potent and direct inducers of apoptosis in cancer cells." J. Cell Sci.,
vol. 124, pp. 556-564 (2011).
Westphal, D., et al. "Molecular biology ofbax and bak activation and
action." Biochim. Biophys. Acta, vol. 1813, pp. 521-531 (2011).
Wolter, K.G., et al. "Movement of bax from the cytosol to
mitochondria during apoptosis." J. Cell Biol., vol. 139, pp. 1281
(1997).
Youle, R.J., et al. "The bcl-2 protein family: opposing activities that
mediate cell death." Nat. Rev. Mo!. Cell. Biol., vol. 9, pp. 47-59
(2008).
Zhang, L., et al. "Role ofbax in the apoptotic response to anticancer
agents." Science, vol. 290, pp. 989 (2000).
Zhou, L., et al. "Dynamics and structure of the bax-bak complex
responsible for releasing mitochondrial proteins during apoptosis." J.
Cell Sci., vol. 121, pp. 2186-2196 (2008).
International Search Report and Written Opinion issued Feb. 1, 2013
for International Patent Application No. PCT/US2012/052354,
which was filed on Aug. 24, 2012 and published as WO 2013/029011
on Feb. 28, 2013 (Inventor-Khaled //Applicant-University of
Central Florida Research Foundation, Inc.) (pp. 1-17).
International Preliminary Report on Patentability issued Apr. 22,
2014 for International Patent Application No. PCT/US2012/052354,
which was filed on Aug. 24, 2012 and published as WO 2013/029011
on Feb. 28, 2013 (Inventor-Khaled //Applicant-University of
Central Florida Research Foundation, Inc.) (pp. 1-13).
Preliminary Amendment filed Jun. 7, 2014 for U.S. Appl. No.
14/363,793 which was filed on Jun. 7, 2014 (Inventor-Khaled //
Applicant-University of Central Florida Research Foundation,
Inc.) (pp. 1-6).
International Search Report and Written Opinion issued Apr. 23,
2013 for International Patent Application No. PCT/US2012/068590,
which was filed on Dec. 7, 2012 and published as WO 2013/086430
on Jun. 13, 2013 (Inventor-Khaled //Applicant-University of
Central Florida Research Foundation, Inc.) (pp. 1-13).
International Preliminary Report on Patentability issued Jun. 10,
2014 for International Patent Application No. PCT/US2012/068590,
which was filed on Dec. 7, 2012 and published as WO 2013/086430
on Jun. 13, 2013 (Inventor-Khaled //Applicant-University of
Central Florida Research Foundation, Inc.) (pp. 1-9).

U.S. Patent

May 26, 2015

A
::L'.
~l

~

b

~y

~

"""'l '

"""~~...::

~

~

x~('

>< x x~<'
< < co
en ·"""

~

~

US 9,040,662 B2

Sheet 1of23

~

::L
0

b

~

::.L
;;4

~
;

~

z<1
x4 x'
~

..

'

\

~ .;~

I

'

v

-<i

~~

c

~

x

x. x
x'
<
< < ro < <
cc
"""' i'.O co
~,

~~

f¥'.

~

22kD

B
!"';
..._
..

C(

"x.•
~

C;t

CZ::

o· ci
!

x
x x
<~
<
<
<
co co ro cc
<

~
:...,

w.
wI

0
x'

::L
WJ
$

~

r..tJ;

,.-,
,....., .:L
.,....,
,.,_

:W

>< >< >< x....'
< <
< < -~
< a:;
cc
~ ~ ·"""
"""
x

!

~,,

"~''"IM
p.,h")
'~

Prohibith1
-.22 k.D

Cy to

Mito

Cvto
~'

Figure 1

Mito

U.S. Patent

May 26, 2015

US 9,040,662 B2

Sheet 2of23

c
Bax-CT20

(~ontrol

Bax-c:·r20-LL

lnt

~;~~)

Wavelength [nm]

~¥.:ivf!f.e!lgth

Figure 1

fnml

U.S. Patent

May 26, 2015

US 9,040,662 B2

Sheet 3of23

QQ

Q

~¢

N

~

~~

I:"~

f"'>~

9
N

"'*

Q
~

~

rIO~tLNO~J

JOPilA-(IU

ll'M

ot.LJ~uu

0

rr]

0 !J~ :)-(l (J

u>

~;i-1
~:
:.:

OLL)-UU

~

0

1~1•
,~11

OZ,t:::>-nn
xgn-'121-uo

N

:tll

rlOltJ.No:·J
.topaA-UO

Cl)
I..

~~M
@k,';]ll
~::::::::::::::~~==:=::'.

::::i
~

~·;::

'M:U OZJ,:J-O(J

't:I

'T'I

0

c

oz.t:)~ou

.c
v

:111 OZ..LJ-U(I
OZ.LJ-O(f

:t::

0

2

xuu-·']:}-(1({
00
M

~

::::
.......

·-.=~

.:::.

e

~

~
~

~
~

~

~

......*

f'-1

"'\

~
i

Q
Q

=
:::
¢

N

~

u

I
~
~

Q

~

¢

Q

t'ltl

'e

::::

fjJ

<C

;

I

~

C>
LL

U.S. Patent

May 26, 2015

US 9,040,662 B2

Sheet 4of23

(.)

Tl·xva

m

U.S. Patent

May 26, 2015

US 9,040,662 B2

Sheet 5of23

("')
Q)

s...

:::l

C>
LL

~"~

{)
~----~'
;,~$

0
~~.

.:--{.

~-~

c~
~'·
~.;i..~

~

t~~

~
~....)

·:.~

<C

::.·:..:t:
$.,,...,..

-~.;f.:)
k
~t.t

~
)'~~·~

~
~

U.S. Patent

May 26, 2015

US 9,040,662 B2

Sheet 6of23

..-.
0

~
(.)

+

a
...

·~--·'

~

<r<

M
Cl)

cc

"':J

,.....
·""""

a
'-

"'-<

a

,""'
;:;

..c

{"'-1

('!

C>
LL

l-M

"'1'"

'~

911 ..L)H

9 t I ,L)H ' ' Xl{ff

U.S. Patent

May 26, 2015

Sheet 7of23

c
BdX
+:

,

--/.,

1 £1
H.... ·c~·T·
· . . . ·.1 l t.

Bax "','/,, .H..(."T ·1 lttc~.)
·t· . .

. .. •·

Figure 3

.

US 9,040,662 B2

U.S. Patent

May 26, 2015

Sheet 8of23

US 9,040,662 B2

s( I l~
~f ... IU\f/0"'
I'•').'
.
. "''" .. ,

'''I
y 1.... I :')rt'
_n_
~ +>..

. '. Xt?<'t'
a

"t--l--s..·

. .·1··. ,I......·')H.
... +I+ ·'xvn
· •·a
91

U.S. Patent

May 26, 2015

Sheet 9of23

S.:IN -H()(l:)/OZJ.:)

US 9,040,662 B2

U.S. Patent

May 26, 2015

US 9,040,662 B2

Sheet 10 of 23

~~~
~~:=;:

~.....

-'!-'''

l~2t\"J::~}

'\'-w

~~
~Un:J<)

-.»

~'

~}'

<:~~ ~~:
·».'-.'

~:

":0

''~:'.~!
~:},"::
,~~-.

ttJ~-~t~~)

u

''-!:.~

'-'::'''
~t~f)tS;;)

U.S. Patent

May 26, 2015

US 9,040,662 B2

Sheet 11 of 23

A

CT20/

B
~:1 . _____________

()

.IJ.nlQad:ed_ _ _ _ _ _

.

·10 1

·10~

H:< 1

JG'

1:J

SVTO.X AA[Narsced·A

Figure 5

·rn'

w~

10°

-rn 1

w'

S·VTO>~ l\l\Dvsni:;ed~"~\

U.S. Patent

May 26, 2015

US 9,040,662 B2

Sheet 12 of 23

c
CT10i

D

CT20/COOH-NPs

{"::;

~'

]JB·

t.t·~3} ~

'\)

::~

Figure 5

.>

B

A

~;/;

;;.;-,

~
;:'.
~~;:.)

~~/,;

Untn:atcd

~j(,

;;~:

Membrane Asymmclry

Necmtii::
(Dead Cdls}

.Membrnm: Asymmdry

,.;::;

{f)

x
;o
~

~;;.-;

;;~;;

1~1:

:0

:~0

~-~.·

}~f~}?.;;

Figure 6

Munbrnnc Asynunctry

~·:.

.:~i.1,v;~l;"r.·.d~,,Z;j;

'1--·'·

., .

.

·,,t?:?~AJ.".,,.,•;-,.;9.(,.Pi?!

~~··;S

.,

~·~

Treatment

ll

0

+Z-VA.D

~f1.=== Ii~~;:
1

~

t;#i~

~

. ~(; ~

.;;J.

•

~

~~..;.

•

:~

+Bd-1

•

t;i/fif$f~,4

n

I

CT20
peptide

«f•

CDDP

CDDP

peptide

CT2.0

'""""""'"I ii~~i;;

~

....

=....

N

N

0--,

°"
=

~

=
=

rJl
\C

d

(.H

N

.....

0

(.H

.....

('D
('D

1J1

Ul

N
0

N
~~

~

~

~

=

~

~

~

~

•

00

U.S. Patent

May 26, 2015

Sheet 14 of 23

c

D

Figure 6

US 9,040,662 B2

U.S. Patent

<(

May 26, 2015

+/+xes

Sheet 15 of 23

US 9,040,662 B2

U.S. Patent

B

May 26, 2015

Sheet 16 of 23

Colocafizatkm of Peptide
to Mitochondria

Figure 7

US 9,040,662 B2

~
"'!

,:;:
Wt""'l

=

~

~:

~- [

~

~·

~

*

~

.(';>

.....
""
~ ~~·'
....::;:

00

-...
~

~

;.

=

EGVP-EE

•t

t

s.
:t

'

EGFP

'

CONTROL

EGFP-KK
EGFP-EE

t:GFP--LL

ti

~

EGFP-RR

I

~
....
'
....
;::;-,

!i

!"':

~ '?

8

I

~

0

i I
N
t·'4

r:"

~

£Z JO l I J<l<lQS

IIJ

EGFP
CONTROL

a

tj

ZH Z99'0P0'6 Sil

EGFP-LL
E(WP-RR

II
GI•

e

"'w

~

EG.FP-KK

II

...~,

..,

EGF'P-RR
EGFP

CONTROL

t

'Tl

C'D

l:GFP--LL

:f

""'
e..

c:

t:GFP-EE

't t•

('}

(C

EGFP~KK

••

(2

~
.....
,....•

~

II

:~

-...., ....

~

·~
II

~

~

~~

ll

~

d

~

~

;·

""

-r

)>

~~ ~

~

I
I

f.'.GFP-KK

E.GFP--EE
EGFP-LL
EGFP-RR
EGFP
CONTROL

,.,..
~

pt

0

SIOZ '9z Atrw

JUaJt?d

·s·n

U.S. Patent

c

(.)

May 26, 2015

Sheet 18 of 23

US 9,040,662 B2

U.S. Patent

May 26, 2015

US 9,040,662 B2

Sheet 19 of 23

B

A

N~uwpartid\i$

with Bnx peptide

calcein concentration (µM)

calcein concentration (µM)

Figure 9

0..

a
0

u

0

'......

UT

0

c

N

u

u

0

I-

0.

0

Cl

u

+

t;

c..
0

u

v

N
!-

Q
....

+

0

a

0..

0

a
v
+

u

c

0

N

4->

c:
0

UT u

0
IN

u

0..

0
0

u

0

N

I-

u

.r-~1

I-

+

0..

0
0

w

Bd-2
Cytosol

Mitochondria
Figure 10

U.S. Patent

May 26, 2015

Sheet 20 of 23

Figure 11

CT2{}
~:'<'r;~0~

(~)~~~·=r::~~ n-;.~=·'\:.t;:f·~~:~~.:
~~.~~y::r:t~~f:.UV}

Figure 12

US 9,040,662 B2

U.S. Patent

PEPTIDE

May 26, 2015

SOURCE

CT20p

US 9,040,662 B2

Sheet 21 of 23

SEQUENCE

%
HYO

VITFVAQVLTASL TIWKKMG

II

NET
CHARGE

STRUCTURE

SEQ
IDNO

lactoferricin

Bos
taurus

FKCRRWQWRMKKLQAPSITCVRRAF

48

lndolicidin

Bos
taurus

ILPWKWPWWPWRR

53

3

beta

40

GI GAVLKVLTTQLPALISWI KRKRQQ

46

5

alpha

41

Mellitin

beta

39

Brevinin 1

Frog

FLPVLAQIAAKVVPALFCKITKKC

66

4

unknown

42

Ranalexin

Frog

FLGQLIKIVPAMICAVTKKC

65

3

alpha

43

Cecropin A

Insect

KWKLFKKIEKVGQNIRDGllKAGPAVAVVGQATQIAK

45

6

alpha

44

Dermaseptin
B2

Frog

ALWKTMLKKLGTMALHAGKAALGAAADTISQGTQ

54

3

alpha

45

Magainin 2

Frog

GIGKFLHSAKKFGKAFVGEIMNS

43

3

alpha

46

CT20p REV

n/a

GMKKWITLSATLVGAVFTIV

60

2

n/a

47

KLA peptide

synthetic

KLAKLAKKLAKLAK

57

6

alpha

48

Bax a5-a6

Human

DGN FNW GRWALFYFASKLVLKVPELI RT

52

2

alpha

49

BIM BH3

Human

MRPEIWIAQELRRIGDEFNA

40

0

unknown

50

BID BH3

Human

EDllRNIARHLAQVGDSMQR

40

0

unknown

51

BAK BH3

Human

GQVGRQLAllGDDINR

40

0

unknown
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METHODS AND COMPOSITIONS
COMPRISING AC-TERMINAL BAX PEPTIDE

prise administering to at least a cell an effective amount of a
C-terminal Bax peptide (CT20p peptide) or a composition
comprising an effective amount of a CT20p peptide.
Disclosed herein is a method of killing cancer cells in a
subject comprising administering to at least one cell of a
subject an effective amount ofCT20p peptide or a composition comprising an effective amount of CT20p peptide. As
used herein, CT20, CT20p peptide or CT20p peptide refers to
a peptide comprising the last 20 amino acids of the Bax
C-terminus.
Disclosed herein is a method of killing microbial cells,
including but not limited to bacteria and fungi, whether on a
surface, present in a colony or in a subject, comprising administering to at least one cell of a subject an effective amount of
a CT20p peptide or a composition comprising an effective
amount of a CT20p peptide.
Disclosed herein is a method of permeabilizing membranes of cells. Such membranes may be outer membranes,
cell membranes or interior cellular membranes. The cells may
be individual cells or cells in a subject. The method comprises
(i) administering an effective amount of a CT20p peptide, and
(ii) forming at least one pore in a membrane of at least one
cell, wherein the peptide or a composition comprising an
effective amount of a CT20p peptide destabilizes at least one
membrane, facilitates ion exchange, and/or causes a sequestered molecule to be released.
Disclosed herein is a method of killing cancer cells in a
subject comprising (i) administering to a subject an effective
amount of a CT20p peptide, (ii) permeabilizing at least one
membrane in a cell of the subject, and (iii) inducing cell death.
Disclosed herein is a method of killing bacterial or fungal
cells in a subject comprising (i) administering to a subject an
effective amount of a CT20p peptide, (ii) permeabilizing at
least one membrane in a cell of the subject, and (iii) inducing
cell death.
Disclosed herein is a composition for permeabilizing
membranes on or in cells comprising a CT20p peptide.
Disclosed herein is a composition for killing cells comprising a CT20p peptide.
Disclosed herein is a composition for permeabilizing lipid
membranes in cells comprising a CT20p peptide and one or
more therapeutic agents, including but not limited to antibiotics, antimycotis, and anti-cancer drugs.
Disclosed herein is a composition for killing cells comprising a CT20p peptide and one or more therapeutic agents,
including but not limited to antibiotics, antimycotis, and anticancer drugs.

CROSS-REFERENCE TO RELATED
APPLICATIONS
This application is a National Phase Application of International Application No. PCT/US2012/052354 filedAug. 24,
2012, which claims priority to U.S. Provisional Application
No. 61/527,524 filed Aug. 25, 2011 and to U.S. Provisional
Application No. 61/645,891 filed May 11, 2012, each of
which is incorporated herein fully by reference.
This invention was made with govermnent support under
GM083324 awarded by the National Institutes of Heath/
NIGMS. The United States government has certain rights in
the invention.
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REFERENCE TO SEQUENCE LISTING
The Sequence Listing submitted Nov. 21, 2014 as a text file
named "21650_0024U2_revised_sequence_listing.txt," created on Nov. 21, 2014 and having a size of 17,889 bytes, is
hereby incorporated by reference pursuant to 37 C.F.R. § 1.52
(e)(5).
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BACKGROUND
The ability to kill cells provides a powerful therapeutic
approach to treatment of disease or infection. Bacteria and
fungi are becoming resistant to many of the currently available antimicrobial or antimycotic therapeutic compounds.
Cancer cells frequently acquire mutations that enhance resistance to standard treatments. Principal among these mechanisms of drug resistance is abnormal expression of members
of the B cell lymphoma-2 (Bcl-2) family (Oltersdorf et al.,
2005). The Bcl-2 family consists of more than twenty antiand pro-apoptotic members that modulate the balance
between life and death. Tumors expressing high levels of
anti-apoptotic proteins, such as Bcl-2, Mcl-1 or Bel-xi, can be
resistant to the effects of chemotherapeutics (Oltersdorf et al.,
2005). This is accomplished, in part, by inhibition of the
pro-apoptotic Bcl-2 family members, such as Bax, first identified as a protein that interacts with Bcl-2 (Oltvai et al.,
1993 ). The association of Bax with mitochondria is linked to
the release of cytochrome c and other death-mediators from
mitochondrial reserves (Eskes et al., 1998).
Bax is a 21 kD protein of 192 amino acids, comprised of
nine alpha helices (Suzuki et al., 2000). Under non-apoptotic
conditions, Bax predominantly resides in the cytosol, with a
small percentage of the protein localized to the mitochondria
(Boohaker et al., 2011; Kaufmann et al., 2003; Putcha et al.,
1999).
Despite advances in understanding the physiology and
pathophysiology of cancer and/or aberrant cell growth, there
is still a scarcity of compounds that are efficacious and safe in
the treatment of cancer and/or aberrant cell growth. Therapeutics that are effective against bacteria and fungi are needed
as these microorganisms grow more resistant to current therapies. These needs and other needs are satisfied by the present
invention.
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SUMMARY
Disclosed herein is a method of permeabilizing membranes of cells. Such membranes may be outer membranes,
cell membranes or interior cellular membranes. The cells may
be individual cells or cells in a subject. Methods may com-
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BRIEF DESCRIPTION OF THE FIGURES
The accompanying figures, which are incorporated in and
constitute a part of this specification, illustrate several aspects
and together with the description serve to explain the principles of the invention.
FIGS. lA and B show distribution of Bax proteins in
lysates. FIG. lA shows that the C-terminus of wild-type Bax
is distributed among cytosolic and mitochondria lysates (A),
while various substitutions at the C-terminus modulates the
association of the full-length protein to the mitochondria
(FIGS. lA and B). FIG. lC shows the results of the analysis
of the effects of mutations in Bax demonstrating that the
C-terminus of Bax mediates membrane permeabilization.
FIG. 2 shows that most of the DD-tagged Bax full length
was found in cytosolic extracts (A), while DD-tagged CT20p
peptide transolated to mitochondria and caused cell death (B
andC).
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FIG. 3 shows schematic representation of the three dimensional structure of aliphatic hyperbranched nanoparticles (A),
cells taking up nanoparticles (B) and (C) that Dil-loaded
nanoparticles result in minimal to no cell death compared to
the positive control (dead cells).
FIG. 4 shows changes in cell morphology, including disruption of mitochondria, cell shrinkage and membrane pertubations that are indicative of cell death of Bax+/+ (A) or
Bax- 1- (B) HCT-116 cells and that cell death was measured
and the loss of membrane integrity was detected within three
hours of treatment with CT20 Bax peptide-nanoparticles (C).
FIG. 5 shows morphological changes in MCF-7 (A) and
MDS-MB-231 (C) cells following treatment with CT20p
peptide nanoparticle (A), with the loss of membrane integrity
detected by 3 hours of treatment in MCF-7 (B) and MDSMB-231 (D).
FIG. 6 shows data for membrane and cellular effects of
CT20p peptide, including that tumor cell death mediated by
the CT20p peptide is independent of effector caspases and is
resistant to Bcl-2 overexpression (A and B). FIG. 6 C-D
shows that CT20p peptide can cause tumor regression in a
mouse model of breast cancer.
FIG. 7 illustrates that the DD-CT20p peptide is co-localized with mitochondria (A) and these observations are quantified and shown in a bar graph (B).
FIG. 8 is an immunoblot that shows the mitochondrial
translocation ofEGFP-tagged with Bax CT (EGFP-KK) and
K189/L190 mutants in Bax+/+ HCT-116 cells (A) and Bax_;_
HCT-116 cells (B). Bax+/+ HCT-116 cells (C) and Bax- 1HCT-116 cells (D) were transfected with EGFP-Kk or K189/
Kl 90 mutants.
FIG. 9 shows the effect of nanoparticles alone (A) or with
BAX peptide (B) on lipid vesicles.
FIG. 10 shows the expression ofBcl-2 in transiently transfected MDA-MB-231 cells.
FIG. 11 shows a model for a membrane pore formed by the
CT20 Bax peptide. Peptide molecules are shown in ribbon
format (A). Top view of the pore formed by CT20p is shown
in CPK format and a calcein molecule is shown within the
pore in a ball and stick format (B).
FIG. 12 shows a hypothetical cell death pathway for CT20p
peptide using a basic model of apoptotic and non-apoptotic
cell death.
FIG. 13 is a table ofCT20p peptide comparison with antimicrobial and apoptosis inducing peptides.
FIG. 14 shows a graph of killing of microbial cells, a
measure of wild type E. coli growth by optical density
(OD280) over 24 hours with increasing concentration of
CT20p. The inhibiting concentration (IC50) was found to be
50 ug of CT20p in 100 mL LB broth.
FIG. 15 shows a graph of killing microbial cells, a measure
of wild type E. coli colony formation after treatment with
both CT20p and Scrambled (SCR) peptide shows that the
minimum inhibitory concentration (MiC) of the CT20p is 25
mg. This was determined by plating the E. coli after treatment
then counting the resulting colonies after 24 hour incubation.
Additional advantages of the invention will be set forth in
part in the description which follows, and in part will be
obvious from the description, or can be learned by practice of
the invention. The advantages of the invention will be realized
and attained by means of the elements and combinations
particularly pointed out in the appended claims. It is to be
understood that both the foregoing general description and
the following detailed description are exemplary and
explanatory only and are not restrictive of the invention, as
claimed.

DETAILED DESCRIPTION
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The present invention comprises methods and compositions for disrupting the cellular membranes of cells. The cells
may be procaryotes or eucaryotes, and may be found as
individual cells, in colonies, on or within multi-celled organisms such as plants or animals. For example, microbial cells
may be found on the surface of an animal, such as a human, or
within the animal. Cancer cells may be found in a subject,
such as a plant, human or animal.
Mitochondria play a central role in regulating both apoptotic and non-apoptotic or necrotic pathways by selectively
releasing cell death promoting factors. The determination as
to whether or not an apoptotic or non-apoptotic cell death
pathway will be activated is dependent on the type of death
mediator released from the mitochondria.
Most current anti-cancer drugs only trigger the apoptotic
pathway. Defects in the apoptotic machinery can contribute to
tumor formation and resistance to treatment, creating a need
to identify anti-cancer agents that kill cells by novel mechanisms. The development of a new therapeutic agent that
induces cell death via a non-apoptotic mechanism and can be
used in combination with standards drugs that induce apoptosis will have significant impact on the treatment of drug
resistance cancers and could greatly improve overall patient
outcomes. As described herein, the death-inducing properties
of the C-terminal (CT) of the alpha-9 helix of Bax, an amphipathic domain with putative membrane binding properties,
were examined.
To examine the cytotoxic potential of the CT domain of
Bax, a peptide (CT20) was generated. The CT20p peptide
permeabilized mitochondrial-like lipid vesicles and caused
cell death. The cell death pathway triggered by the CT20p
peptide was independent of effector caspases and resistant to
Bcl-2 over-expression. This indicates that the CT20p peptide
can be used in combinatorial therapies to sensitize drugresistant cancer cells to treatment. Other properties of the
CT20 Bax peptide, show that the CT20p peptide causes cell
membrane permeability, and such a peptide may be combined
with antimicrobial therapeutics or therapies to cause cell
death in microorganisms, such as gram-positive and gramnegative bacteria, other types of bacteria, fungi and other
microorganisms and infectious agents.
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Disclosed herein are compositions comprising a CT20p
peptide.
1. Compositions for Permeabilizing Membranes in Cells
Disclosed herein is a composition for permeabilizing
membranes in cells comprising a CT20p peptide. The cells
may be individual cells, or cells that are on or in a subject. In
an aspect, the cells are eukaryotic or prokaryotic cells, including but not limited to bacteria and fungi. In an aspect, the cells
are in a subject. In an aspect, the cells are on a surface, which
may be inert or may be the surface of a subject. In an aspect,
the cells are cancer cells or transformed cells. In an aspect, the
cancer cell can be a cell from any type of cancer including, but
not limited to, cancer of the head and neck cancer, esophagus,
stomach, pancreas, kidney, bladder, bone, brain, and cervix.
In an aspect, the cancer is breast cancer. In an aspect, the
cancer is colorectal cancer. In an aspect, the cancer is lung
cancer. In an aspect, the cancer is a drug resistant cancer. In an
aspect, the cancer cell is a drug resistant cancer cell. In an
aspect, a disclosed composition comprising a truncated Bax
peptide is administered directly into a tumor.
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In an aspect, a disclosed composition for permeabilizing
peutic drugs. In an aspect, a disclosed composition comprismembranes in cells forms one or more pores in the meming a CT20p peptide further comprises one or more radio senbranes of the cells. In an aspect, the membrane may be an
sitizers.
outer membrane, a cellular membrane or an organelle memIn an aspect, a disclosed composition for permeabilizing
brane. In an aspect, the membrane is a mitochondrial memmembranes in cells comprising a CT20p peptide further comprises (i) one or more anti-cancer drugs, (ii) one or more
brane. In an aspect, the one or more pores are formed in a
mitochondrial membrane of a cancer cell.
chemotherapeutic drugs, and (iii) one or more radiosensitizers. In an aspect, a disclosed composition further comprises
In an aspect, a disclosed composition for permeabilizing
one or more anti-cancer drugs and one or more chemotheramembranes in cells destabilizes a cellular membrane. In an
aspect, a disclosed composition facilitates ion exchange. In an 10 peutic drugs. In an aspect, a disclosed composition further
aspect, a disclosed composition causes a sequestered molcomprises one or more anti-cancer drugs and one or more
ecule to be released. In an aspect, a disclosed composition
radio sensitizers. In an aspect, a disclosed composition further
destabilizes a cellular membrane, facilitates ion exchange,
comprises one or more chemotherapeutic drugs and one or
more radiosensitizers.
and causes a sequestered molecule to be released. In an
aspect, a disclosed composition destabilizes a cellular mem- 15
In an aspect, a disclosed composition for permeabilizing
membranes in cells is administered to a subject. In an aspect,
brane and facilitates ion exchange. In an aspect, a disclosed
composition destabilizes a cellular membrane and causes a
the subject is a manimal. In an aspect, the manimal is a
sequestered molecule to be released. In an aspect, a disclosed
primate. In an aspect, the mammal is a human. In an aspect,
composition facilitates ion exchange and causes a sequesthe human is a patient.
tered molecule to be released.
20
In an aspect, a disclosed composition for permeabilizing
In an aspect, a disclosed composition for permeabilizing
membranes in cells comprising a CT20p peptide is adminismembranes in cells comprising a CT20p peptide induces cell
tered to a subject at least two times. In an aspect, a disclosed
death. In an aspect, the cell death mimics necrosis. In an
composition is administered to the subject two or more times.
aspect, the cell death occurs independent of endogenous Bax
In an aspect, a disclosed composition is administered at rouactivity. In an aspect, the cell death occurs independent of 25 tine or regular intervals. For example, in an aspect, a disclosed
endogenous caspase activity. In an aspect, the cell death is
composition is administered to the subject one time per day,
resistant to Bcl-2 over-expression.
or two times per day, or three or more times per day. In an
aspect, a disclosed composition is administered to the subject
In an aspect, a disclosed composition for permeabilizing
membranes in cells comprising a CT20p peptide induces cell
daily, or one time per week, or two times per week, or three or
death, wherein (i) the cell death mimics necrosis, (ii) the cell 30 more times per week, etc. In an aspect, a disclosed composition is administered to the subject weekly, or every other
death occurs independent of endogenous Bax activity, (iii) the
cell death occurs independent of endogenous caspase activity,
week, or every third week, or every fourth week, etc. In an
or (iv) the cell death is resistant to Bcl-2 over-expression, or
aspect, a disclosed composition is administered to the subject
(v) the cell death exhibits a combination thereof.
monthly, or every other month, or every third month, or every
In an aspect, a pore-forming composition may comprise an 35 fourth month, etc. In an aspect, the repeated administration of
amount of a CT20p peptide so that pores comprising from two
a disclosed composition occurs over a pre-determined or defito ten peptides, from two to eight peptides, from four to ten
nite duration of time. In an aspect, the repeated administration
peptides, from five, six, seven, eight, nine, ten or more pepof a disclosed composition occurs over an indefinite period of
tides, can be formed.
time.
In an aspect, following the administration of a disclosed
In an aspect, a disclosed composition for permeabilizing 40
membranes in cells comprises a CT20p peptide comprising
composition for permeabilizing membranes in cells comprisSEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3,and/orSEQID
ing a CT20p peptide, the cells are sensitized to treatment. In
NO: 4. For example, in an aspect, a disclosed CT20p peptide
an aspect, following the administration of a disclosed comis VTIFVAGVLTASLTIWKKMG (SEQ ID NO: 1). In an
position comprising a CT20p peptide, a subject is sensitized
aspect, a disclosed CT20p peptide is VTIFVAGVLTASLTI- 45 to treatment. In an aspect, an increased sensitivity or a
WEEMG (SEQ ID NO: 2). In an aspect, a disclosed CT20p
reduced sensitivity to a treatment, such as a therapeutic treatpeptide is VTIFVAGVLTASLTIWLLMG (SEQ ID NO: 3).
ment, is measured according to one or more methods as
In an aspect, a disclosed CT20p peptide is VTIFVAGVLknown in the art for the particular treatment. In an aspect,
TASLTIWRRMG (SEQ ID NO: 4). In an aspect, a disclosed
methods of measuring sensitivity to a treatment include, but
composition for permeabilizing membranes in cells com- 50 not limited to, cell proliferation assays and cell death assays.
prises one or more CT20 Bax peptides, wherein the one or
In an aspect, the sensitivity of a cell or a subject to treatment
more CT20 Bax peptides comprise SEQ ID NO: 1, SEQ NO:
can be measured or determined by comparing the sensitivity
2, SEQ ID NO: 3; or SEQ ID NO: 4.
of a cell or a subject following administration of a disclosed
In an aspect, a CT20p peptide of a disclosed composition
composition comprising a CT20p peptide to the sensitivity of
for permeabilizing membranes in cells is encapsulated in 55 a cell or subject that has not been administered a disclosed
polymeric nanoparticles. In an aspect, the nanoparticles are
composition comprising a CT20p peptide.
aminated. In an aspect, the nanoparticles are carboxylated.
For example, in an aspect, following the administration of
a disclosed composition for permeabilizing membranes in
In an aspect, a disclosed composition for permeabilizing
cells comprising a CT20p peptide, the cell is 2-fold, 3-fold,
membranes in cells comprising a CT20p peptide further comprises one or more therapeutic compounds, such as one or 60 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold,
12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold,
more antimicrobial compounds, one or more antibacterial
19-fold, 20-fold, or greater, more sensitive to treatment than a
compounds, one or more antifungal compounds, or one or
more anti-cancer drugs, or a combination thereof. In an
cell that has not been administered a disclosed composition
aspect, the one or more anti-cancer drugs comprise cisplatin.
comprising a CT20p peptide. In an aspect, following the
In an aspect, the one or more anti-cancer drugs induce apop- 65 administration of a disclosed composition comprising a
CT20p peptide the cell is 2-fold, 3-fold, 4-fold, 5-fold, 6-fold,
tosis. In an aspect, a disclosed composition comprising a
7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold,
CT20p peptide further comprises one or more chemothera-
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14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, 20-fold,
or greater, less resistant to treatment than a cell that has not
been administered a disclosed composition comprising a
CT20p peptide. The determination of a cell's or a subject's
sensitivity or resistance is routine in the art and within the
skill of an ordinary clinician and/or researcher.
In an aspect, the determination of a cell's or a subject's
sensitivity or resistance to treatment can be monitored. For
example, in an aspect, data regarding sensitivity or resistance
can be acquired periodically, such as every week, every other
week, every month, every other month, every 3 months, 6
months, 9 months, or every year, every other year, every 5
years, every 10 years for the life of the subject, for example,
a human subject or patient with cancer and/or aberrant cell
growth. In an aspect, data regarding sensitivity or resistance
can be acquired at various rather than at periodic times. In an
aspect, treatment for a subject can be modified based on data
regarding a cell's or a subject's sensitivity or resistance to
treatment. For example, in an aspect, the treatment can modified by changing the dose of a disclosed compositions, the
route of administration of a disclosed compositions, the frequency of administration of a disclosed composition, etc.
Disclosed herein is a composition for permeabilizing lipid
membranes in cells comprising a CT20p peptide and one or
more anti-cancer drugs.
2. Compositions for Killing Cells
Disclosed herein is a composition for killing cells comprising a CT20p peptide. In an aspect, the cells are eukaryotic or
prokaryotic cells, including but not limited to bacteria and
fungi. In an aspect, the cells are in a subject. In an aspect, the
cells are on a surface, which may be inert or may be the
surface of a subject. In an aspect, the cells are cancer cells or
transformed cells. In an aspect, the cancer cell can be a cell
from any type of cancer including, but not limited to, cancer
of the head and neck cancer, esophagus, stomach, pancreas,
kidney, bladder, bone, brain, and cervix. In an aspect, the
cancer is breast cancer. In an aspect, the cancer is colorectal
cancer. In an aspect, the cancer is lung cancer. In an aspect, the
cancer is a drug resistant cancer. In an aspect, the cancer cell
is a drug resistant cancer cell. In an aspect, a disclosed composition comprising a CT20p peptide is administered directly
into a tumor.
In an aspect, a disclosed composition for killing cells forms
one or more pores in the membranes of the cells. In an aspect,
the membrane may be an outer membrane, a cellular membrane or an organelle membrane. In an aspect, the membrane
is a mitochondrial membrane. In an aspect, the one or more
pores are formed in a mitochondrial membrane. In an aspect,
the one or more pores are formed in a mitochondrial membrane of a cancer cell.
In an aspect, a disclosed composition for killing cells destabilizes a cellular membrane. In an aspect, a disclosed composition facilitates ion exchange. In an aspect, a disclosed
composition causes a sequestered molecule to be released. In
an aspect, a disclosed composition destabilizes a cellular
membrane, facilitates ion exchange, and causes a sequestered
molecule to be released. In an aspect, a disclosed composition
destabilizes a cellular membrane and facilitates ion exchange.
In an aspect, a disclosed composition destabilizes a cellular
membrane and causes a sequestered molecule to be released.
In an aspect, a disclosed composition facilitates ion exchange
and causes a sequestered molecule to be released.
In an aspect, a disclosed composition for killing cells comprising a CT20p peptide induces cell death. In an aspect, the
cell death mimics necrosis. In an aspect, the cell death occurs
independent of endogenous Bax activity. In an aspect, the cell

death occurs independent of endogenous caspase activity. In
an aspect, the cell death is resistant to Bcl-2 over-expression.
In an aspect, a disclosed composition for killing cells comprising a CT20p peptide induces cell death, wherein (i) the
cell death mimics necrosis, (ii) the cell death occurs independent of endogenous Bax activity, (iii) the cell death occurs
independent of endogenous caspase activity, or (iv) the cell
death is resistant to Bcl-2 over-expression, or (v) the cell
death exhibits a combination thereof.
In an aspect, a composition for killing cells comprises a
pore-forming composition which may comprise an amount of
a CT20p peptide so that pores comprising from two to ten
peptides, from two to eight peptides, from four to ten peptides, from five, six, seven, eight, nine, ten or more peptides,
can be formed.
In an aspect, a disclosed composition for killing cells comprises a CT20p peptide comprising SEQ ID NO: 1, SEQ ID
NO: 2, SEQ ID NO: 3, and/or SEQ ID NO: 4. For example, in
an aspect, a disclosed CT20p peptide is VTIFVAGVLTASLTIWKKMG (SEQ ID NO: 1). In an aspect, a disclosed
CT20p peptide is VTIFVAGVLTASLTIWEEMG (SEQ ID
NO: 2). In an aspect, a disclosed CT20p peptide is
VTIFVAGVLTASLTIWLLMG (SEQ ID NO: 3). In an
aspect, a disclosed CT20p peptide is VTIFVAGVLTASLTIWRRMG (SEQ ID NO: 4). In an aspect, a disclosed composition for killing cells comprises one or more CT20 Bax
peptides, wherein the one or more CT20 Bax peptides comprise SEQ ID NO: 1, SEQ NO: 2, SEQ ID NO: 3; or SEQ ID
N0:4.
In an aspect, a CT20p peptide of a disclosed composition
for killing cells is encapsulated in polymeric nanoparticles. In
an aspect, the nanoparticles are aminated. In an aspect, the
nanoparticles are carboxylated.
In an aspect, a disclosed composition for killing cells comprising a CT20p peptide further comprises one or more therapeutic compounds, such as one or more antimicrobial compounds, one or more antibacterial compounds, one or more
antifungal compounds, or one or more anti-cancer drugs, or a
combination thereof. In an aspect, the one or more anti-cancer
drugs comprise cisplatin. In an aspect, the one or more anticancer drugs induce apoptosis. In an aspect, a disclosed composition for killing cells comprising a CT20p peptide further
comprises one or more chemotherapeutic drugs. In an aspect,
a disclosed composition for killing cells comprising a CT20p
peptide further comprises one or more radiosensitizers.
In an aspect, a disclosed composition for killing cells comprising a CT20p peptide further comprises (i) one or more
anti-cancer drugs, (ii) one or more chemotherapeutic drugs,
and (iii) one or more radiosensitizers. In an aspect, a disclosed
composition for killing cells further comprises one or more
anti-cancer drugs and one or more chemotherapeutic drugs.
In an aspect, a disclosed composition for killing cells further
comprises one or more anti-cancer drugs and one or more
radiosensitizers. In an aspect, a disclosed composition for
killing cells further comprises one or more chemotherapeutic
drugs and one or more radiosensitizers.
In an aspect, a disclosed composition for killing cells is
administered to a subject. In an aspect, the subject is a mammal. In an aspect, the mammal is a primate. In an aspect, the
mammal is a human. In an aspect, the human is a patient.
In an aspect, a disclosed composition for killing cells comprising a CT20p peptide is administered to a subject at least
two times. In an aspect, a disclosed composition is administered to the subject two or more times. In an aspect, a disclosed composition is administered at routine or regular intervals. For example, in an aspect, a disclosed composition is
administered to the subject one time per day, or two times per

10

15

20

25

30

35

40

45

50

55

60

65

US 9,040,662 B2
9

10

day, or three or more times per day. In an aspect, a disclosed
composition is administered to the subject daily, or one time
per week, or two times per week, or three or more times per
week, etc. In an aspect, a disclosed composition is administered to the subject weekly, or every other week, or every third
week, or every fourth week, etc. In an aspect, a disclosed
composition is administered to the subject monthly, or every
other month, or every third month, or every fourth month, etc.
In an aspect, the repeated administration of a disclosed composition occurs over a pre-determined or definite duration of
time. In an aspect, the repeated administration of a disclosed
composition occurs over an indefinite period of time.
In an aspect, following the administration of a disclosed
composition for killing cells comprising a CT20p peptide, the
cells are sensitized to treatment. In an aspect, following the
administration of a disclosed composition for killing cells
comprising a CT20p peptide, a subject is sensitized to treatment. In an aspect, an increased sensitivity or a reduced
sensitivity to a treatment, such as a therapeutic treatment, is
measured according to one or more methods as known in the
art for the particular treatment. In an aspect, methods of
measuring sensitivity to a treatment include, but not limited
to, cell proliferation assays and cell death assays. In an aspect,
the sensitivity of a cell or a subject to treatment can be measured or determined by comparing the sensitivity of a cell or
a subject following administration of a disclosed composition
for killing cells comprising a CT20p peptide to the sensitivity
of a cell or subject that has not been administered a disclosed
composition for killing cells comprising a CT20p peptide.
For example, in an aspect, following the administration of
a disclosed composition for killing cells comprising a CT20p
peptide, the cell is 2-fold, 3-fold, 4-fold, 5-fold, 6-fold,
7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold,
14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, 20-fold,
or greater, more sensitive to treatment than a cell that has not
been administered a disclosed composition for killing cells
comprising a CT20p peptide. In an aspect, following the
administration of a disclosed composition for killing cells
comprising a CT20p peptide, the cell is 2-fold, 3-fold, 4-fold,
5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold,
12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold,
19-fold, 20-fold, or greater, less resistant to treatment than a
cell that has not been administered a disclosed composition
for killing cells comprising a CT20p peptide. The determination of a cell's or a subject's sensitivity or resistance is routine
in the art and within the skill of an ordinary clinician and/or
researcher.
In an aspect, the determination of a cell's or a subject's
sensitivity or resistance to treatment can be monitored. For
example, in an aspect, data regarding sensitivity or resistance
can be acquired periodically, such as every week, every other
week, every month, every other month, every 3 months, 6
months, 9 months, or every year, every other year, every 5
years, every 10 years for the life of the subject, for example,
a human subject or patient with cancer and/or aberrant cell
growth. In an aspect, data regarding sensitivity or resistance
can be acquired at various rather than at periodic times. In an
aspect, treatment for a subject can be modified based on data
regarding a cell's or a subject's sensitivity or resistance to
treatment. For example, in an aspect, the treatment can modified by changing the dose of a disclosed compositions, the
route of administration of a disclosed compositions, the frequency of administration of a disclosed composition, etc.
Disclosed herein is a composition for killing cells comprising a CT20p peptide and one or more anti-cancer drugs.

3. Pharmaceutical Compositions
In an aspect, the invention relates to pharmaceutical compositions comprising a disclosed composition for permeabilizing membranes in cells. In an aspect, the invention relates
to pharmaceutical compositions comprising a disclosed composition for killing cells. In an aspect, the disclosed compositions for permeabilizing membranes and cells and for killing cells comprise a CT20 Bax peptide. In an aspect, a
pharmaceutical composition can be provided comprising a
therapeutically effective amount of at least one disclosed
composition and a pharmaceutically acceptable carrier.
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1. Permeabilizing Membranes of Cells
Disclosed herein are methods of permeabilizing membranes of cells. The cells may be individual cells, or cells that
are on or in a subject. In an aspect, the cells are eukaryotic or
prokaryotic cells, including but not limited to bacteria and
fungi.
In an aspect, disclosed herein is a method of permeabilizing membranes of cells in a subject comprising administering
to at least a cell a CT20p peptide. In an aspect, disclosed
herein is a method of permeabilizing membranes of cells in a
subject comprising administering to at least a cell a composition comprising an effective amount of a CT20p peptide. In
an aspect, the membrane may be an outer membrane, a cellular membrane or an organelle membrane. In an aspect the
cell is a bacterial cell. In an aspect, the cell is a fungal cell. In
an aspect, the cell is a microbial cell. In an aspect, the cell is
a cancer cell or a transformed cell. In an aspect, the cancer cell
can be a cell from any type of cancer including, but not limited
to, cancer of the head and neck cancer, esophagus, stomach,
pancreas, kidney, bladder, bone, brain, and cervix. In an
aspect, the cancer is breast cancer. In an aspect, the cancer is
colorectal cancer. In an aspect, the cancer is lung cancer. In an
aspect, the cancer is a drug resistant cancer. In an aspect, the
cancer cell is a drug resistant cancer cell. In an aspect, a
CT20p peptide or a composition comprising an effective
amount of a CT20p peptide is administered directly into a
tumor.
In an aspect of a disclosed a method of permeabilizing
membranes of cells, a CT20p peptide or a composition comprising an effective amount of a CT20p peptide forms at least
one pore in the membrane of the cell. In an aspect, a CT20p
peptide or a composition comprising an effective amount of a
CT20p peptide forms two or more pores in the membrane of
the cell. In an aspect, cell is a cancer cell. In an aspect, the one
or more pores are formed in a mitochondrial membrane. In an
aspect, the one or more pores are formed in a mitochondrial
membrane of a cancer cell.
In an aspect of a disclosed method of permeabilizing membranes of cells in a subject, a CT20p peptide or a composition
comprising an effective amount of a CT20p peptide destabilizes a cellular membrane, facilitates ion exchange, and
causes a sequestered molecule to be released. In an aspect, a
CT20p peptide or a composition comprising an effective
amount of a CT20p peptide destabilizes a cellular membrane.
In an aspect, a CT20p peptide or a composition comprising an
effective amount of a CT20p peptide facilitates ion exchange,
exchange. In an aspect, a CT20p peptide or a composition
comprising an effective amount of a CT20p peptide causes a
sequestered molecule to be released. In an aspect, a CT20p
peptide or a composition comprising an effective amount of a
CT20p peptide destabilizes a cellular membrane and facilitates ion exchange. In an aspect, a CT20p peptide or a composition comprising an effective amount of a CT20p peptide
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destabilizes a cellular membrane and causes a sequestered
molecule to be released. In an aspect, a CT20p peptide or a
composition comprising an effective amount of a CT20p
peptide facilitates ion exchange and causes a sequestered
molecule to be released.
In an aspect, following the administration of a CT20p
peptide or a composition comprising an effective amount of a
CT20p peptide, the cells are sensitized to treatment. In an
aspect, following the administration of CT20p peptide or a
composition comprising an effective amount of a CT20p
peptide, a subject is sensitized to treatment. In an aspect, an
increased sensitivity or a reduced sensitivity to a treatment,
such as a therapeutic treatment, is measured according to one
or more methods as known in the art for the particular treatment. In an aspect, methods of measuring sensitivity to a
treatment include, but not limited to, cell proliferation assays
and cell death assays. In an aspect, the sensitivity of a cell or
a subject to treatment can be measured or determined by
comparing the sensitivity of a cell or a subject following
administration of a CT20p peptide or a composition comprising an effective amount of a CT20p peptide to the sensitivity
of a cell or subject that has not been administered a CT20p
peptide or a composition comprising an effective amount of a
CT20p peptide.
For example, in an aspect, following the administration of
a CT20p peptide or a composition comprising an effective
amount of a CT20p peptide, the cell is 2-fold, 3-fold, 4-fold,
5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold,
12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold,
19-fold, 20-fold, or greater, more sensitive to treatment than a
cell that has not been administered a CT20p peptide or a
disclosed composition comprising an effective amount of a
CT20p peptide. In an aspect, following the administration of
a CT20p peptide or a composition comprising an effective
amount of a CT20p peptide, the cell is 2-fold, 3-fold, 4-fold,
5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold,
12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold,
19-fold, 20-fold, or greater, less resistant to treatment than a
cell that has not been administered a CT20p peptide or a
disclosed composition comprising an effective amount of a
CT20p peptide. The determination of a cell's or a subject's
sensitivity or resistance is routine in the art and within the
skill of an ordinary clinician and/or researcher.
In an aspect, the determination of a cell's or a subject's
sensitivity or resistance to treatment can be monitored. For
example, in an aspect, data regarding sensitivity or resistance
can be acquired periodically, such as every week, every other
week, every month, every other month, every 3 months, 6
months, 9 months, or every year, every other year, every 5
years, every 10 years for the life of the subject, for example,
a human subject or patient with cancer and/or aberrant cell
growth. In an aspect, data regarding sensitivity or resistance
can be acquired at various rather than at periodic times. In an
aspect, treatment for a subject can be modified based on data
regarding a cell's or a subject's sensitivity or resistance to
treatment. For example, in an aspect, the treatment can modified by changing the dose of a disclosed compositions, the
route of administration of a disclosed compositions, the frequency of administration of a disclosed composition, etc.
In an aspect, a disclosed method of permeabilizing membranes of cells in a subject further comprises repeating the
administration a CT20p peptide or a composition comprising
an effective amount of a CT20p peptide. In an aspect, a
CT20p peptide or a composition comprising an effective
amount of a CT20p peptide is administered to the subject at
least two times. In an aspect, a CT20p peptide or a composition comprising an effective amount of a CT20p peptide is

administered to the subject two or more times. In an aspect, a
CT20p peptide or a composition comprising an effective
amount of a CT20p peptide administered at routine or regular
intervals. For example, in an aspect, a CT20p peptide or a
composition comprising an effective amount of a CT20p
peptide is administered to the subject one time per day, or two
times per day, or three or more times per day. In an aspect, a
CT20p peptide or a composition comprising an effective
amount of a CT20p peptide is administered to the subject
daily, or one time per week, or two times per week, or three or
more times per week, etc. In an aspect, a CT20p peptide or a
composition comprising an effective amount of a CT20p
peptide is administered to the subject weekly, or every other
week, or every third week, or every fourth week, etc. In an
aspect, a CT20p peptide or a composition comprising an
effective amount of a CT20p peptide is administered to the
subject monthly, or every other month, or every third month,
or every fourth month, etc. In an aspect, the repeated administration of a CT20p peptide or a composition comprising an
effective amount of a CT20p peptide occurs over a pre-determined or definite duration of time. In an aspect, the repeated
administration of a CT20p peptide or a composition comprising an effective amount of a CT20p peptide occurs over an
indefinite period of time.
In an aspect, a disclosed method of permeabilizing membranes of cells in a subject further comprises inducing cell
death. In an aspect, cell death mimics necrosis. In an aspect,
cell death occurs independent of endogenous Bax activity. In
an aspect, cell death occurs independent of endogenous
caspase activity. In an aspect, cell death is resistant to Bcl-2
over-expression.
In an aspect, a disclosed method of permeabilizing membranes of cells in a subject comprising administering a CT20p
peptide or a composition comprising an effective amount of a
CT20p peptide further comprises inducing cell death. Cell
death may include, but is not limited to wherein (i) cell death
mimics necrosis, (ii) cell death occurs independent of endogenous Bax activity, (iii) cell death occurs independent of
endogenous caspase activity, or (iv) cell death is resistant to
Bcl-2 over-expression, or (v) cell death exhibits a combination thereof.
In an aspect, a CT20p peptide or a composition comprising
an effective amount of a CT20p peptide of a disclosed method
of permeabilizing cell membranes comprises SEQ ID NO: 1,
SEQ ID NO: 2, SEQ ID NO: 3, and/or SEQ ID NO: 4. For
example, in an aspect, a CT20p peptide is VTIFVAGVLTASLTIWKKIVIG (SEQ ID NO: 1). In an aspect, a CT20p
peptide is VTIFVAGVLTASLTIWEEMG (SEQ ID NO: 2).
In an aspect, a CT20p peptide is VTIFVAGVLTASLTIWLLMG (SEQ ID NO: 3). In an aspect, a CT20p peptide is
VTIFVAGVLTASLTIWRRMG (SEQ ID NO: 4). In an
aspect, a disclosed composition comprising an effective
amount of a CT20p peptide comprises one or more CT20 Bax
peptides, wherein the one or more CT20 Bax peptides comprise SEQ ID NO: 1, SEQ NO: 2, SEQ ID NO: 3; or SEQ ID
NO: 4, or two or more of each. In an aspect, a CT20p peptide
of a disclosed method of permeabilizing membranes of cells
in a subject is encapsulated in polymeric nanoparticles. In an
aspect, the nanoparticles are aminated. In an aspect, the nanoparticles are carboxylated.
In an aspect, a disclosed method of permeabilizing membranes comprising administering a CT20p peptide or a composition comprising an effective amount of a CT20p peptide
further comprises administering one or more anti-cancer
drugs. In an aspect, the one or more anti-cancer drugs comprise cisplatin. In an aspect, the one or more anti-cancer drugs
induce apoptosis. In an aspect, a disclosed method of perme-
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abilizing membranes compnsmg administering a CT20p
peptide or a composition comprising an effective amount of a
CT20p peptide further comprises administering one or more
chemotherapeutic drugs. In an aspect, a disclosed method of
permeabilizing membranes comprising administering a
CT20p peptide or a composition comprising an effective
amount of a CT20p peptide further comprises administering
one or more radiosensitizers.
In an aspect, a disclosed method of permeabilizing membranes comprising administering a CT20p peptide or a composition comprising an effective amount of a CT20p peptide
further comprises administering (i) one or more anti-cancer
drugs, (ii) one or more chemotherapeutic drugs, and (iii) one
or more radiosensitizers. In an aspect, a disclosed method
further comprises administering one or more anti-cancer
drugs and one or more chemotherapeutic drugs. In an aspect,
a disclosed method further comprises administering one or
more anti-cancer drugs and one or more radiosensitizers. In
an aspect, a disclosed method further comprises administering one or more chemotherapeutic drugs and one or more
radio sensitizers.
In an aspect of a disclosed method of permeabilizing membranes of cells, which may be in or on a subject, the subject is
a manmial. In an aspect, the mammal is a primate. In an
aspect, the manmial is a human. In an aspect, the human is a
patient.
In an aspect, disclosed herein is a method of permeabilizing membranes of cells in a subject comprising (i) administering to a subject an effective amount of a CT20p peptide or
a composition comprising an effective amount of a CT20p
peptide, and (ii) forming at least one pore in a membrane of at
least one cell of the subject, wherein the peptide destabilizes
at least one membrane, facilitates ion exchange, and/or causes
a sequestered molecule to be released.
2. Killing Cancer Cells
Disclosed herein are methods of killing cancer cells.
In an aspect, disclosed herein is a method of killing cancer
cells in a subject comprising administering to at least one cell
of a subject an effective amount of a CT20p peptide. In an
aspect, disclosed herein is a method of killing cancer cells in
a subject comprising administering to at least one cell of a
subject a composition comprising an effective amount of a
CT20p peptide. In an aspect, the cell is a cancer cell or a
transformed cell. In an aspect, the cancer cell can be a cell
from any type of cancer including, but not limited to, cancer
of the head and neck cancer, esophagus, stomach, pancreas,
kidney, bladder, bone, brain, and cervix. In an aspect, the
cancer is breast cancer. In an aspect, the cancer is colorectal
cancer. In an aspect, the cancer is lung cancer. In an aspect, the
cancer is a drug resistant cancer. In an aspect, the cancer cell
is a drug resistant cancer cell. In an aspect, a CT20p peptide
or a composition comprising an effective amount of a CT20p
peptide is administered directly into a tumor.
In an aspect, a disclosed method of killing cancer cells in a
subject further comprises permeabilizing at least one membrane in the cell. In an aspect, the membrane is a mitochondrial membrane. In an aspect, the one or more pores are
formed in a mitochondrial membrane. In an aspect, the one or
more pores are formed in a mitochondrial membrane of a
cancer cell.
In an aspect, permeabilizing at least one membrane in the
cell comprises destabilizing a cellular membrane, facilitating
ion exchange, and causing a sequestered molecule to be
released. In an aspect, permeabilizing at least one membrane
in the cell comprises destabilizes a cellular membrane. In an
aspect, permeabilizing at least one membrane in the cell
comprises facilitating ion exchange. In an aspect, permeabi-

lizing at least one membrane in the cell comprises causing a
sequestered molecule to be released. In an aspect, permeabilizing at least one membrane in the cell comprises destabilizing a cellular membrane and facilitating ion exchange. In an
aspect, permeabilizing at least one membrane in the cell
comprises destabilizing a cellular membrane and causing a
sequestered molecule to be released. In an aspect, permeabilizing at least one membrane in the cell comprises facilitating
ion exchange and causing a sequestered molecule to be
released.
In an aspect of a disclosed method of killing cancer cells in
a subject, the cancer cells are sensitized to treatment. In an
aspect of a disclosed method of killing cancer cells in a
subject, the subject is sensitized to treatment. In an aspect, an
increased sensitivity or a reduced sensitivity to a treatment,
such as a therapeutic treatment, is measured according to one
or more methods as known in the art for the particular treatment. In an aspect, methods of measuring sensitivity to a
treatment include, but not limited to, cell proliferation assays
and cell death assays. In an aspect, the sensitivity of a cell or
a subject to treatment can be measured or determined by
comparing the sensitivity of a cell or a subject following
administration of a CT20p peptide or a composition comprising a CT20p peptide to the sensitivity of a cell or subject that
has not been administered a CT20p peptide or a composition
comprising a CT20p peptide.
For example, in an aspect, following the administration of
a CT20p peptide or a composition comprising a CT20p peptide, the cell is 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold,
8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold,
15-fold, 16-fold, 17-fold, 18-fold, 19-fold, 20-fold, or
greater, more sensitive to treatment than a cell that has not
been administered a CT20p peptide or a composition comprising a CT20p peptide. In an aspect, following the administration of a CT20p peptide or a composition comprising a
CT20p peptide, the cell is 2-fold, 3-fold, 4-fold, 5-fold,
6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold,
13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold,
20-fold, or greater, less resistant to treatment than a cell that
has not been administered a CT20p peptide or a composition
comprising a CT20p peptide. The determination of a cell's or
a subject's sensitivity or resistance is routine in the art and
within the skill of an ordinary clinician and/or researcher.
In an aspect, the determination of a cell's or a subject's
sensitivity or resistance to treatment can be monitored. For
example, in an aspect, data regarding sensitivity or resistance
can be acquired periodically, such as every week, every other
week, every month, every other month, every 3 months, 6
months, 9 months, or every year, every other year, every 5
years, every 10 years for the life of the subject, for example,
a human subject or patient with cancer and/or aberrant cell
growth. In an aspect, data regarding sensitivity or resistance
can be acquired at various rather than periodic times. In an
aspect, treatment for a subject can be modified based on data
regarding a cell's or a subject's sensitivity or resistance to
treatment.
In an aspect, a disclosed method of killing cancer cells in a
subject further comprises repeating the administration of a
CT20p peptide or a composition comprising an effective
amount of a CT20p peptide. In an aspect, a CT20p peptide or
a composition comprising an effective amount of a CT20p
peptide is administered to the subject at least two times. In an
aspect, a CT20p peptide or a composition comprising an
effective amount of a CT20p peptide is administered to the
subject two or more times. In an aspect, a CT20p peptide or a
composition comprising an effective amount of a CT20p
peptide is administered at routine or regular intervals. For
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example, in an aspect, a CT20p peptide or a composition
comprises administering (i) one or more anti-cancer drugs,
comprising an effective amount of a CT20p peptide is admin(ii) one or more chemotherapeutic drugs, and (iii) one or more
istered to the subject one time per day, or two times per day,
radiosensitizers. In an aspect, a disclosed method for killing
or three or more times per day. In an aspect, a CT20p peptide
cancer cells further comprises administering one or more
or a composition comprising an effective amount of a CT20p
anti-cancer drugs and one or more chemotherapeutic drugs.
peptide is administered to the subject daily, or one time per
In an aspect, a disclosed method for killing cancer cells furweek, or two times per week, or three or more times per week,
ther comprises administering one or more anti-cancer drugs
etc. In an aspect, a CT20p peptide or a composition comprisand one or more radiosensitizers. In an aspect, a disclosed
ing an effective amount of a CT20p peptide is administered to
method for killing cancer cells further comprises administerthe subject weekly, or every other week, or every third week, 10 ing one or more chemotherapeutic drugs and one or more
or every fourth week, etc. In an aspect, a CT20p peptide or a
radio sensitizers.
In an aspect of a disclosed method of killing cancer cells in
composition comprising an effective amount of a CT20p
peptide is administered to the subject monthly, or every other
a subject, the subject is a manimal. In an aspect, the mammal
month, or every third month, or every fourth month, etc. In an
is a primate. In an aspect, the mammal is a human. In an
aspect, the repeated administration of a CT20p peptide or a 15 aspect, the human is a patient.
composition comprising an effective amount of a CT20p
Disclosed herein is a method of killing cancer cells in a
subject comprising (i) administering to a subject an effective
peptide occurs over a pre-determined or definite duration of
time. In an aspect, the repeated administration of a CT20p
amount of a CT20p peptide, (ii) permeabilizing at least one
membrane in a cell of the subject, and (iii) inducing cell death.
peptide or a composition comprising an effective amount of a
3. Killing Cancer Cells
CT20p peptide occurs over an indefinite period of time.
20
Disclosed herein are methods of killing microbial cells.
In an aspect, a disclosed method of killing cancer cells in a
In an aspect, disclosed herein is a method of killing microsubject further comprises inducing cell death. In an aspect,
cell death mimics necrosis. In an aspect, cell death occurs
bial cells in a subject comprising administering to at least one
independent of endogenous Bax activity. In an aspect, cell
cell of a subject an effective amount of a CT20p peptide. In an
death occurs independent of endogenous caspase activity. In 25 aspect, disclosed herein is a method of killing microbial cells
an aspect, cell death is resistant to Bcl-2 over-expression. In
in a subject comprising administering to at least one cell of a
an aspect, a disclosed method of killing cancer cells induces
subject a composition comprising an effective amount of a
CT20p peptide. In an aspect, the cell is a microbial cell,
cell death, wherein (i) cell death mimics necrosis, (ii) cell
including eukaryotic and prokaryotic cells, such as bacteria
death occurs independent of endogenous Bax activity, (iii)
cell death occurs independent of endogenous caspase activity, 30 and/or fungi. Inan aspect, the cell is a drug resistant microbial
or (iv) cell death is resistant to Bcl-2 over-expression, or (v)
cell. In an aspect, a CT20p peptide or a composition compriscell death exhibits a combination thereof.
ing an effective amount of a CT20p peptide is administered
directly.
In an aspect, a CT20p peptide of a disclosed method of
killing cells comprises SEQ ID NO: 1, SEQ ID NO: 2, SEQ
In an aspect, a disclosed method of killing microbial cells
ID NO: 3, and/or SEQ ID NO: 4. For example, in an aspect, a 35 in a subject further comprises permeabilizing at least one
C-terminal truncated Bax is VTIFVAGVLTASLTIWKKMG
membrane in the cell. In an aspect, the membrane is a mito(SEQ ID NO: 1). In an aspect, a CT20p peptide is
chondrial membrane. In an aspect, the one or more pores are
VTIFVAGVLTASLTIWEEMG (SEQ ID NO: 2). In an
formed in a mitochondrial membrane. In an aspect, the one or
aspect, a CT20p peptide is VTIFVAGVLTASLTIWLLMG
more pores are formed in a mitochondrial membrane of a
(SEQ ID NO: 3). In an aspect, a CT20p peptide is 40 microbial cell.
In an aspect, permeabilizing at least one membrane in the
VTIFVAGVLTASLTIWRRMG (SEQ ID NO: 4). In an
aspect, a disclosed composition comprising an effective
cell comprises destabilizing a cellular membrane, facilitating
amount of a CT20p peptide comprises one or more CT20 Bax
ion exchange, and causing a sequestered molecule to be
released. In an aspect, permeabilizing at least one membrane
peptides, wherein the one or more CT20 Bax peptides comprise SEQ ID NO: 1, SEQ NO: 2, SEQ ID NO: 3; or SEQ ID 45 in the cell comprises destabilizes a cellular membrane. In an
N0:4.
aspect, permeabilizing at least one membrane in the cell
comprises facilitating ion exchange. In an aspect, permeabiIn an aspect, a CT20p peptide of a disclosed method of
lizing at least one membrane in the cell comprises causing a
killing cancer cells in a subject is encapsulated in polymeric
sequestered molecule to be released. In an aspect, permeabinanoparticles. In an aspect, the nanoparticles are aminated. In
an aspect, the nanoparticles are carboxylated.
50 lizing at least one membrane in the cell comprises destabilizIn an aspect, a disclosed method for killing cancer cells
ing a cellular membrane and facilitating ion exchange. In an
aspect, permeabilizing at least one membrane in the cell
comprising administering a CT20p peptide or a composition
comprising an effective amount of a CT20p peptide further
comprises destabilizing a cellular membrane and causing a
comprises administering one or more anti-cancer drugs. In an
sequestered molecule to be released. In an aspect, permeabiaspect, the one or more anticancer drugs comprise cisplatin. 55 lizing at least one membrane in the cell comprises facilitating
In an aspect, the one or more anti-cancer drugs induce apopion exchange and causing a sequestered molecule to be
released.
tosis. In an aspect, a disclosed method for killing cancer cells
In an aspect of a disclosed method ofkilling microbial cells
comprising administering a CT20p peptide or a composition
comprising an effective amount of a CT20p peptide further
in a subject, the microbial cells are sensitized to treatment. In
comprises administering one or more chemotherapeutic 60 an aspect of a disclosed method of killing microbial cells in a
drugs. In an aspect, a disclosed method for killing cancer cells
subject, the subject is sensitized to treatment. In an aspect, an
comprising administering a CT20p peptide or a composition
increased sensitivity or a reduced sensitivity to a treatment,
comprising an effective amount of a CT20p peptide further
such as a therapeutic treatment, is measured according to one
comprises administering one or more radiosensitizers.
or more methods as known in the art for the particular treatIn an aspect, a disclosed method for killing cancer cells 65 ment. In an aspect, methods of measuring sensitivity to a
treatment include, but not limited to, cell proliferation assays
comprising administering a CT20p peptide or a composition
comprising an effective amount of a CT20p peptide further
and cell death assays. In an aspect, the sensitivity of a cell or
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a subject to treatment can be measured or determined by
comparing the sensitivity of a cell or a subject following
administration of a CT20p peptide or a composition comprising a CT20p peptide to the sensitivity of a cell or subject that
has not been administered a CT20p peptide or a composition
comprising a CT20p peptide.
For example, in an aspect, following the administration of
a CT20p peptide or a composition comprising a CT20p peptide, the cell is 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold,
8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold,
15-fold, 16-fold, 17-fold, 18-fold, 19-fold, 20-fold, or
greater, more sensitive to treatment than a cell that has not
been administered a CT20p peptide or a composition comprising a CT20p peptide. In an aspect, following the administration of a CT20p peptide or a composition comprising a
CT20p peptide, the cell is 2-fold, 3-fold, 4-fold, 5-fold,
6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold,
13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold,
20-fold, or greater, less resistant to treatment than a cell that
has not been administered a CT20p peptide or a composition
comprising a CT20p peptide. The determination of a cell's or
a subject's sensitivity or resistance is routine in the art and
within the skill of an ordinary clinician and/or researcher.
In an aspect, the determination of a cell's or a subject's
sensitivity or resistance to treatment can be monitored. For
example, in an aspect, data regarding sensitivity or resistance
can be acquired periodically, such as every week, every other
week, every month, every other month, every 3 months, 6
months, 9 months, or every year, every other year, every 5
years, every 10 years for the life of the subject, for example,
a human subject. In an aspect, data regarding sensitivity or
resistance can be acquired at various rather than periodic
times. In an aspect, treatment for a subject can be modified
based on data regarding a cell's or a subject's sensitivity or
resistance to treatment.
In an aspect, a disclosed method of killing microbial cells
in a subject further comprises repeating the administration of
a CT20p peptide or a composition comprising an effective
amount of a CT20p peptide. In an aspect, a CT20p peptide or
a composition comprising an effective amount of a CT20p
peptide is administered to the subject at least two times. In an
aspect, a CT20p peptide or a composition comprising an
effective amount of a CT20p peptide is administered to the
subject two or more times. In an aspect, a CT20p peptide or a
composition comprising an effective amount of a CT20p
peptide is administered at routine or regular intervals. For
example, in an aspect, a CT20p peptide or a composition
comprising an effective amount of a CT20p peptide is administered to the subject one time per day, or two times per day,
or three or more times per day. In an aspect, a CT20p peptide
or a composition comprising an effective amount of a CT20p
peptide is administered to the subject daily, or one time per
week, or two times per week, or three or more times per week,
etc. In an aspect, a CT20p peptide or a composition comprising an effective amount of a CT20p peptide is administered to
the subject weekly, or every other week, or every third week,
or every fourth week, etc. In an aspect, a CT20p peptide or a
composition comprising an effective amount of a CT20p
peptide is administered to the subject monthly, or every other
month, or every third month, or every fourth month, etc. In an
aspect, the repeated administration of a CT20p peptide or a
composition comprising an effective amount of a CT20p
peptide occurs over a pre-determined or definite duration of
time. In an aspect, the repeated administration of a CT20p
peptide or a composition comprising an effective amount of a
CT20p peptide occurs over an indefinite period of time.

In an aspect, a disclosed method of killing microbial cells
in a subject further comprises inducing cell death. In an
aspect, cell death mimics necrosis. In an aspect, cell death
occurs independent of endogenous Bax activity. In an aspect,
cell death occurs independently of endogenous caspase activity. In an aspect, cell death is resistant to Bcl-2 over-expression. In an aspect, a disclosed method of killing cells induces
cell death, wherein (i) cell death mimics necrosis, (ii) cell
death occurs independent of endogenous Bax activity, (iii)
cell death occurs independent of endogenous caspase activity,
or (iv) cell death is resistant to Bcl-2 over-expression, or (v)
cell death exhibits a combination thereof.
In an aspect, a CT20p peptide of a disclosed method of
killing cells comprises SEQ ID NO: 1, SEQ ID NO: 2, SEQ
ID NO: 3, and/or SEQ ID NO: 4. For example, in an aspect, a
C-terminal truncated Bax is VTIFVAGVLTASLTIWKKMG
(SEQ ID NO: 1). In an aspect, a CT20p peptide is
VTIFVAGVLTASLTIWEEMG (SEQ ID NO: 2). In an
aspect, a CT20p peptide is VTIFVAGVLTASLTIWLLMG
(SEQ ID NO: 3). In an aspect, a CT20p peptide is
VTIFVAGVLTASLTIWRRMG (SEQ ID NO: 4). In an
aspect, a disclosed composition comprising an effective
amount of a CT20p peptide comprises one or more CT20 Bax
peptides, wherein the one or more CT20 Bax peptides comprise SEQ ID NO: 1, SEQ NO: 2, SEQ ID NO: 3; or SEQ ID
N0:4.
In an aspect, a CT20p peptide of a disclosed method of
killing microbial cells in a subject is encapsulated in polymeric nanoparticles. In an aspect, the nanoparticles are aminated. In an aspect, the nanoparticles are carboxylated.
In an aspect, a disclosed method for killing microbial cells
comprising administering a CT20p peptide or a composition
comprising an effective amount of a CT20p peptide further
comprises administering one or more anti-microbial drugs. In
an aspect, a disclosed method for killing microbial cells comprising administering a CT20p peptide or a composition comprising an effective amount of a CT20p peptide further comprises administering one or more chemotherapeutic drugs. In
an aspect, a disclosed method for killing cancer cells comprising administering a CT20p peptide or a composition comprising an effective amount of a CT20p peptide further comprises administering one or more antimicrobial therapeutics
or therapies.
In an aspect of a disclosed method ofkilling microbial cells
in or on a subject, the subject is a mammal. In an aspect, the
mammal is a primate. In an aspect, the mammal is a human. In
an aspect, the human is a patient.
Disclosed herein is a method of killing microbial cells in a
subject comprising (i) administering to a subject an effective
amount of a CT20p peptide, (ii) permeabilizing at least one
membrane in a cell of the subject, and (iii) inducing cell death.
4. Other Uses
Also disclosed herein are uses of a disclosed composition
as an investigational and/or research tool in the development
and standardization of in vitro and in vivo test systems for
evaluation in laboratory animals such as cats, dogs, rabbits,
monkeys, rats and mice, as part of the search for (i) new
therapeutic approaches for permeabilizing membranes of
cells and for killing cancerormicrobial cells as well as (ii) the
evaluation of the permeabilization of membranes of cells and
for the killing of cancer or microbial cells. In an aspect, the
search for new therapeutic approaches and the evaluation of
new therapeutic approaches involves a subject, such as a
human subject or human patient.
Methods ofkilling microbial organisms on an inert surface.
The present invention comprises methods of treating a
surface to render it antimicrobial, comprising contacting a
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CT20p peptide composition comprising CT20p peptide to a
surface. The peptides may be air-dried and remain on the
surface or may be affixed to the surface by binding to other
proteins or binding-partners on the surface, or may be
attached by adhesive compounds or other compounds known
for attaching proteins to a surface, or the peptides may remain
in solution in a liquid or semisolid or other form that contacts
the surface. The CT20p peptide composition may comprise
SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3,and/orSEQID
NO: 4, or a combination of two or more of SEQ ID NOs 1-4.
When a surface treated with a CT20p peptide composition
comprising one or more CT20p peptides is then contacted by
microbial organisms, it is believed that the cellular membranes of the microbial organisms are permeabilized and
microbial death may occur.

In general, the biological activity or biological action of a
peptide refers to any function exhibited or performed by the
peptide that is ascribed to the naturally occurring form of the
peptide as measured or observed in vivo (i.e., in the natural
physiological environment of the protein) or in vitro (i.e.,
under laboratory conditions). For example, a biological activity of the CT20p peptide is the cytotoxic activity of the CT20
Bax peptide.
Theterm "enzyme" as used herein refers to any peptide that
catalyzes a chemical reaction of other substances without
itself being destroyed or altered upon completion of the reaction. Typically, a peptide having enzymatic activity catalyzes
the formation of one or more products from one or more
substrates. Such peptides can have any type of enzymatic
activity including, without limitation, the enzymatic activity
or enzymatic activities associated with enzymes such as those
disclosed herein.
References in the specification and concluding claims to
parts by weight of a particular element or component in a
composition denotes the weight relationship between the element or component and any other elements or components in
the composition or article for which a part by weight is
expressed. Thus, in a compound containing 2 parts by weight
of component X and 5 parts by weight component Y, X and Y
are present at a weight ratio of 2:5, and are present in such
ratio regardless of whether additional components are contained in the compound.
A weight percent (wt. % ) of a component, unless specifically stated to the contrary, is based on the total weight of the
formulation or composition in which the component is
included.
As used herein, the terms "optional" or "optionally" means
that the subsequently described event or circumstance can or
can not occur, and that the description includes instances
where said event or circumstance occurs and instances where
it does not.
As used herein, the terms "transformation" and "transfection" mean the introduction of a nucleic acid, e.g., an expression vector, into a recipient cell including introduction of a
nucleic acid to the chromosomal DNA of said cell. The art is
familiar with various compositions, methods, techniques, etc.
used to effect the introduction of a nucleic acid into a recipient
cell. The art is familiar with such compositions, methods,
techniques, etc for both eukaryotic and prokaryotic cells. The
art is familiar with such compositions, methods, techniques,
etc. forthe optimization of the introduction and expression of
a nucleic acid into and within a recipient cell.
As used herein, "a CT20p peptide" may refer to one peptide or may refer one or more peptides, such as molar concentrations of the peptide, as would be found in a composition. Those skilled in the art understand where an individual
peptide is intended and where a molar, or smaller or larger
amount, of many of the same peptide are intended.
As used herein, the term "subject" refers to the target of
administration, e.g., an animal. Thus, the subject of the herein
disclosed methods can be a vertebrate, such as a manimal, a
fish, a bird, a reptile, or an amphibian. Alternatively, the
subject of the herein disclosed methods can be a human,
non-human primate, horse, pig, rabbit, dog, sheep, goat, cow,
cat, guinea pig or rodent. The term does not denote a particular age or sex. Thus, adult and newborn subjects, as well as
fetuses, whether male or female, are intended to be covered.
In one aspect, the subject is a patient. A patient refers to a
subject afflicted with a disease or disorder, such as, for
example, cancer and/or aberrant cell growth. The term
"patient" includes human and veterinary subjects. In some
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0003. Definitions
Unless otherwise expressly stated, it is in no way intended
that any method or aspect set forth herein be construed as
requiring that its steps be performed in a specific order.
Accordingly, where a method claim does not specifically state
in the claims or descriptions that the steps are to be limited to
a specific order, it is no way intended that an order be inferred,
in any respect. This holds for any possible non-express basis
for interpretation, including matters of logic with respect to
arrangement of steps or operational flow, plain meaning
derived from grammatical organization or punctuation, or the
number or type of aspects described in the specification.
As used in the specification and the appended claims, the
singular forms "a," "an" and "the" include plural referents
unless the context clearly dictates otherwise.
The word "or" as used herein means any one member of a
particular list and also includes any combination of members
of that list.
Ranges can be expressed herein as from "about" one particular value, and/or to "about" another particular value.
When such a range is expressed, a further aspect includes
from the one particular value and/or to the other particular
value. Similarly, when values are expressed as approximations, by use of the antecedent "about," it will be understood
that the particular value forms a further aspect. It will be
further understood that the endpoints of each of the ranges are
significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that
there are a number of values disclosed herein, and that each
value is also herein disclosed as "about" that particular value
in addition to the value itself. For example, ifthe value "10"
is disclosed, then "about 10" is also disclosed. It is also
understood that each unit between two particular units are
also disclosed. For example, if 10 and 15 are disclosed, then
11, 12, 13, and 14 are also disclosed.
As used herein, the amino acid abbreviations are conventional one letter codes for the amino acids and are expressed
as follows: A, alanine; B, asparagine or aspartic acid; C,
cysteine; D aspartic acid; E, glutamate, glutamic acid; F,
phenylalanine; G, glycine; H histidine; I isoleucine; K,
lysine; L, leucine; M, methionine; N, asparagine; P, praline;
Q, glutamine; R, arginine; S, serine; T, threonine; V, valine;
W, tryptophan; Y, tyrosine; Z, glutamine or glutamic acid.
"Peptide" as used herein refers to any peptide, oligopeptide, polypeptide, gene product, expression product, or protein. For example, a peptide can be a fragment ofa full-length
protein, such as, for example, the CT20 Bax peptide. A peptide is comprised of consecutive amino acids. The term "peptide" encompasses naturally occurring or synthetic molecules.
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aspects of the disclosed methods, the subject has been diagnosed with a need fortreatment for cancer and/or aberrant cell
growth.
Therapeutic agents may include antimicrobial agents, such
as antibiotics or antimycotic compounds, including but not
limited to, active agents such as antifungal agents, antibacterial agents, anti-viral agents and antiparasitic agents, and
metals. An antimicrobial agent may comprise a substance,
compound or molecule, that kills or inhibits the growth of
microorganisms such as bacteria, fungi, or protozoans. Antimicrobial agents may either kill microbes (microbiocidal) or
prevent the growth of microbes (microbiostatic). Disinfectants are antimicrobial substances used on non-living objects
or outside the body. Anitmicrobial agents include those
obtained from natural sources, such as Beta-lactam antibiotics (such as penicillins, cephalosporins), and protein synthesis inhibitors (such as aminoglycosides, macrolides, tetracyclines, chloramphenicol, polypeptides), and those from
synthetic sources such as sulphonamides, cotrimoxazole,
quinolones, anti-fungals, anti-cancer drugs, antimalarials,
anti-tuberculosis drugs, anti-leprotics, and anti-protozoals.
Examples of antimicrobial agents that can be used in the
present invention include, but are not limited to, isoniazid,
ethambutol, pyrazinamide, streptomycin, clofazimine,
rifabutin,
fluoroquinolones,
ofloxacin,
sparfloxacin,
rifampin, azithromycin, clarithromycin, dapsone, tetracycline, erythromycin, ciprofloxacin, doxycycline, ainpicillin,
amphotericin B, ketoconazole, fluconazole, pyrimethamine,
sulfadiazine, clindamycin, lincomycin, pentamidine, atovaquone, paromomycin, diclazaril, acyclovir, trifluorouridine,
foscarnet, penicillin, gentamicin, ganciclovir, iatroconazole,
miconazole, Zn-pyrithione, heavy metals including, but not
limited to, gold, platinum, silver, zinc and copper, and their
combined forms including, salts, such as chloride, bromide,
iodide and periodate, and complexes with carriers, and other
forms. As used herein, the term metal includes all metal salts
or metal compounds, including, but not limited to, metal
chlorides, metal phosphates, metal sulfates, metal iodides or
metal bromides. The active form of some metal salts is the
ionic form. Other antimicrobial agents include, but are not
limited to, polyene antifungals, Amphotericin B, Candicidin,
Filipin, Hamycin, Natamycin, Nystatin, Rimocidin, Imidazoles, Bifonazole, Butoconazole, Clotrimazole, Econazole,
Fenticonazole, Isoconazole, Ketoconazole, Miconazole,
Omoconazole, Oxiconazole, Sertaconazole, Sulconazole,
Tioconazole, Triazoles, Albaconazole, Fluconazole, Isavuconazole, Itraconazole, Posaconazole, Ravuconazole, Terconazole, Voriconazole, Thiazoles, Abafungin, Allylamines,
Amorolfin, Butenafine, Naftifine, Terbinafine, Echinocandins, Anidulafungin, Caspofungin, Micafungin.
Examples of microbial organisms that may be treated by
the present invention include, but are not limited to, pathogenic fungi including, but not limited to, Candida species,
Aspergillus species, Cryptococcus species, histoplasa species, stachybotrus species, and pneumacystus species; bacteria including but not limited to:

-continued

Acetobacter aurantius
Acinetobacter baumannii
Actinomyces israelii
Agrobacterium radiobacter
Agrobacterium tumefaciens
Azorhizobium caulinodans
Azotobacter vinelandii
Anaplasma
Anaplasma phagocytophilum
Acetobacter aurantius

Calymmatobacterium granulomatis
Campylobacter
Campylobacter coli
Campylobacter fetus
Campylobacter jejuni
Campylobacter pylori
Chlamydia
Chlamydia trachomatis
Chlamydophila
Chlamydophila pneumoniae
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Bacillus
Bacillus anthracis
Bacillus brevis
Bacillus cereus
Bacillus fusiformis
Bacillus licheniformis
Bacillus megaterium
Bacillus mycoides
Bacillus stearothermophilus
Bacillus subtilis
Bacteroides
Bacteroidesfragilis
Bacteroides gingivalis
Bacteroides melaninogenicus
Bartonella
Bartonella henselae
Bartonella quintana
Bordetella
Bordetella bronchiseptica
Bordetella pertussis
Borrelia burgdorferi
Brucella
Brucella abortus
Brucella melitensis
Gardnerella vaginalis
Klebsiella pneumoniae
Lactobacillus
Lactobacillus acidophilus
Lactobacillus casei
Lactococcus lactis
Legionella pneumophila
Listeria monocytogenes
Lactobacillus Bulgaricus
Mycoplasma
Mycoplasmafermentans
Mycoplasma genitalium
Mycoplasma hominis
Mycaplasma penetrans
Mycoplasma pneumoniae
Methanobacterium extroquens
Microbacterium multiforme
Micrococcus luteus
Moraxella catarrhalis
Mycobacterium
Mycobacterium avium
Mycobacterium bovis
Mycobacterium diphtheriae
Mycobacterium intracellulare
Mycobacterium leprae
Mycobacterium lepraemurium
Mycobacterium phlei
Mycobacterium smegmatis
Mycobacterium tuberculosis
Pasteurella
Pasteurella multocida
Pasteurella tularensis
Peptostreptococcus
Porphyromonas gingivalis
Pseudomonas aeruginosa
Streptococcus mitior
Streptococcus mitis
Streptococcus mutans
Streptococcus oralis
Streptococcus pneumoniae
Streptococcus pyogenes
Streptococcus rattus
Streptococcus salivarius
Treponema
Treponema pallidum
Treponema denticola
Vibrio
Vibrio cholerae
Vibrio comma

Chlamydophila psittaci
Clostridium
Clostridium botulinum
Clostridium difficile
Clostridium perfringens
Clostridium tetani
Corynebacterium
Corynebacterium diphtheriae
Corynebacteriumfusiforme
Coxiella bumetii
Ehrlichia chaffeensis
Enterobacter cloacae
Enterococcus
Enterococcus avium
Enterococcus durans
Enterococcus faecalis
Enterococcus faecium
Enterococcus galllinarum
Enterococcus maloratus
Escherichia coli
Francisella tularensis
Fusobacterium nucleatum
Haemophilus
Haemophilus ducreyi
Haemophilus infiuenzae
Haemophilus parainfiuenzae
Haemophilus pertussis
Haemophilus vaginalis
Helicobacter pylori
Neisseria
Neisseria gonorrhoeae
Neisseria meningi,tidis
Rhizobium radiobacter
Rickettsia
Rickettsia prowazekii
Rickettsia psittaci
Rickettsia quintana
Rickettsia rickettsii
Rickettsia trachomae
Rochalimaea
Rochalimaea henselae
Rochalimaea quintana
Rothia dentocariosa
Rhizobium radiobacter
Salmonella
Salmonella enteritidis
Salmonella typhi
Salmonella typhimurium
Serratia marcescens
Shigella dysenteriae
Staphylococcus
Staphylococcus aureus
Staphylococcus epidermidis
Stenotrophomonas maltophilia
Streptococcus
Streptococcus agalactiae
Streptococcus avium
Streptococcus bovis
Streptococcus cricetus
Streptococcus faceium
Streptococcus faecalis
Streptococcus ferus
Streptococcus gallinarum
Streptococcus lactis
Streptococcus sanguis
Streptococcus sobrinus
Wolbachia
Vibrio parahaemolyticus
Vibrio vulnificus
Yersinia
Yersinia enterocolitica
Yersinia pestis
Yersinia pseudotuberculosis

The terms "treating", "treatment'', "therapy", and "therapeutic treatment" as used herein refer to curative therapy,
prophylactic therapy, or preventative therapy. As used herein,
the terms refers to the medical management of a subject or a
patient with the intent to cure, ameliorate, stabilize, or prevent
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a disease, pathological condition, or disorder, such as, for
example, cancer or a tumor. This term includes active treatment, that is, treatment directed specifically toward the
improvement of a disease, pathological condition, or disorder, disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated
disease, pathological condition, or disorder. In addition, this
term includes palliative treatment, that is, treatment designed
for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or
completely inhibiting the development of the associated disease, pathological condition, or disorder; and supportive
treatment, that is, treatment employed to supplement another
specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder. In various
aspects, the term covers any treatment of a subject, including
a marmnal (e.g., a human), and includes: (i) preventing the
disease from occurring in a subject that can be predisposed to
the disease but has not yet been diagnosed as having it; (ii)
inhibiting the disease, i.e., arresting its development; or (iii)
relieving the disease, i.e., causing regression of the disease. In
an aspect, the disease, pathological condition, or disorder is
cancer, such as, for example, breast cancer, lung cancer, colorectal, liver cancer, or pancreatic cancer.
As used herein, the term "prevent" or "preventing" refers to
precluding, averting, obviating, forestalling, stopping, or hindering something from happening, especially by advance
action. It is understood that where reduce, inhibit or prevent
are used herein, unless specifically indicated otherwise, the
use of the other two words is also expressly disclosed.
As used herein, the term "diagnosed" means having been
subjected to a physical examination by a person of skill, for
example, a physician or a researcher, and found to have a
condition that can be diagnosed or treated by compositions or
methods disclosed herein. For example, "diagnosed with cancer" means having been subjected to a physical examination
by a person of skill, for example, a physician or a researcher,
and found to have a condition that can be diagnosed or treated
by a compound or composition that alleviates or ameliorates
cancer and/or aberrant cell growth.
As used herein, the phrase "identified to be in need of
treatment for a disorder," or the like, refers to selection of a
subject based upon need for treatment of the disorder. For
example, a subject can be identified as having a need for
treatment of a disorder (e.g., a disorder related to cancer
and/or aberrant cell growth) based upon an earlier diagnosis
by a person of skill and thereafter subjected to treatment for
the disorder. It is contemplated that the identification can, in
one aspect, be performed by a person different from the
person making the diagnosis. It is also contemplated, in a
further aspect, that the administration can be performed by
one who subsequently performed the administration.
As used herein, the terms "administering" and "administration" refer to any method of providing a peptide (such as a
CT20 Bax peptide), or a composition (such as a composition
comprising a CT20 Bax peptide), or pharmaceutical preparation (such as a preparation comprising a CT20p peptide or
a composition comprising a CT20 Bax peptide) to a subject.
Such methods are well known to those skilled in the art and
include, but are not limited to, intracardiac administration,
oral administration, transdermal administration, administration by inhalation, nasal administration, topical administration, intravaginal administration, ophthalmic administration,
intraaural administration, intracerebral administration, rectal
administration, sublingual administration, buccal administration, and parenteral administration, including injectable such

as intravenous administration, intraarterial administration,
intramuscular administration, and subcutaneous administration. Administration can be continuous or intermittent. In
various aspects, a preparation can be administered therapeutically; that is, administered to treat an existing disease or
condition. In further various aspects, a preparation can be
administered prophylactically; that is, administered for prevention of a disease or condition.
The term "contacting" as used herein refers to bringing a
disclosed composition or peptide or pharmaceutical preparation and a cell, target receptor, or other biological entity
together in such a marmer that the compound can affect the
activity of the target (e.g., receptor, transcription factor, cell,
etc.), either directly; i.e., by interacting with the target itself,
or indirectly; i.e., by interacting with another molecule, cofactor, factor, or protein on which the activity of the target is
dependent.
As used herein, the term "determining" can refer to measuring or ascertaining a quantity or an amount or a change in
expression and/or activity level, e.g., of a nucleotide or transcript or polypeptide. For example, determining the amount
of a disclosed transcript or polypeptide in a sample as used
herein can refer to the steps that the skilled person would take
to measure or ascertain some quantifiable value of the transcript or polypeptide in the sample. The art is familiar with the
ways to measure an amount of the disclosed nucleotides,
transcripts, polypeptides, etc.
In an aspect, "determining" as used herein can refer to
measuring or ascertaining the level of cell death or cell survival, for example, following administration of a CT20p peptide or a composition comprising an effective amount of a
CT20p peptide. Methods of measuring or ascertaining cell
survival and cell death are known to the art and include, but
are not limited to, histochemical staining (e.g., TUNEL ), cell
proliferation assay, cell death assays, morphological examination, etc. In an aspect, the size of a tumor can be measured
non-invasively through ultrasound.
As used herein, the term "level" refers to the amount of a
target molecule in a sample, e.g., a sample from a subject. The
amount of the molecule can be determined by any method
known in the art and will depend in part on the nature of the
molecule (i.e., gene, mRNA, cDNA, protein, enzyme, etc.).
The art is familiar with quantification methods for nucleotides (e.g., genes, cDNA, mRNA, etc) as well as proteins,
polypeptides, enzymes, etc. It is understood that the amount
or level of a molecule in a sample need not be determined in
absolute terms, but can be determined in relative terms (e.g.,
when compare to a control or a sham or an untreated sample).
As used herein, the terms "effective amount" and "amount
effective" refer to an amount that is sufficient to achieve the
desired result or to have an effect on an undesired condition.
For example, in an aspect, an effective amount of a CT20p
peptide is an amount that permeabilizes cell membranes and/
or kills cells without causing extraneous damage to surrounding non-cancerous cells. For example, a "therapeutically
effective amount" refers to an amount that is sufficient to
achieve the desired therapeutic result or to have an effect on
undesired symptoms, but is generally insufficient to cause
adverse side affects. The specific therapeutically effective
dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the
severity of the disorder; the specific composition employed;
the age, body weight, general health, sex and diet of the
patient; the time of administration; the route of administration; the rate of excretion of the specific compound employed;
the duration of the treatment; drugs used in combination or
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coincidental with the specific compound employed and like
factors well known in the medical arts.
By "modulate" is meant to alter, by increase or decrease.
As used herein, a "modulator" can mean a composition that
can either increase or decrease the expression level or activity
level of a gene or gene product such as a peptide. Modulation
in expression or activity does not have to be complete. For
example, expression or activity can be modulated by about
10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%,
99%, 100% or any percentage in between as compared to a
control cell wherein the expression or activity of a gene or
gene product has not been modulated by a composition.
As used herein, "EC50 ,'' is intended to refer to the concentration or dose of a substance (e.g., a CT20p peptide or a
disclosed composition comprising a CT20p peptide) that is
required for 50% enhancement or activation of a biological
process, or component of a process, including a protein, subunit, organelle, ribonucleoprotein, etc. EC 50 also refers to the
concentration or dose of a substance that is required for 50%
enhancement or activation in vivo, as further defined elsewhere herein. Alternatively, EC 50 can refer to the concentration or dose of compound that provokes a response hal:!Way
between the baseline and maximum response. The response
can be measured in an in vitro or in vivo system as is convenient and appropriate for the biological response of interest.
For example, the response can be measured in vitro using
cultured cancer cells or in an ex vivo organ culture system
with isolated cancer cells, e.g., pancreatic cancer cells, breast
cancer cells, liver cancer cells, lung cancer cells, colorectal
cancer cells, etc.). Alternatively, the response can be measured in vivo using an appropriate research model such as
rodent, including mice and rats. The mouse or rat can be an
inbred strain with phenotypic characteristics of interest such
as, for example, cancer and/or aberrant cell growth. As appropriate, the response can be measured in a transgenic or knockout mouse or rat wherein a gene or genes has been introduced
or knocked-out, as appropriate, to replicate a disease process.
As used herein, "IC50 ,'' is intended to refer to the concentration or dose of a substance (e.g., a CT20p peptide or a
disclosed composition comprising a CT20p peptide) that is
required for 50% inhibition or diminution of a biological
process, or component of a process, including a protein, subunit, organelle, ribonucleoprotein, etc. IC 50 also refers to the
concentration or dose of a substance that is required for 50%
inhibition or diminution in vivo, as further defined elsewhere
herein. Alternatively, IC 50 also refers to the half maximal
(50%) inhibitory concentration (IC) or inhibitory dose of a
substance. The response can be measured in an in vitro or in
vivo system as is convenient and appropriate for the biological response of interest. For example, the response can be
measured in vitro using cultured cancer cells or in an ex vivo
organ culture system with isolated cancer cells (e.g., breast
cancer cells, pancreatic cancer cells, liver cancer cells, lung
cancer cells, colorectal cancer cells, etc.). Alternatively, the
response can be measured in vivo using an appropriate
research model such as rodent, including mice and rats. The
mouse or rat can be an inbred strain with phenotypic characteristics of interest such as, for example, cancer and/or aberrant cell growth. As appropriate, the response can be measured in a transgenic or knockout mouse or rat wherein a gene
or genes has been introduced or knocked-out, as appropriate,
to replicate a disease process.
The term "pharmaceutically acceptable" describes a material that is not biologically or otherwise undesirable, i.e.,
without causing an unacceptable level of undesirable biological effects or interacting in a deleterious manner. As used
herein, the term "pharmaceutically acceptable carrier" refers

to sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just
prior to use. Examples of suitable aqueous and nonaqueous
carriers, diluents, solvents or vehicles include water, ethanol,
polyols (such as glycerol, propylene glycol, polyethylene
glycol and the like), carboxymethylcellulose and suitable
mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be
maintained, for example, by the use of coating materials such
as lecithin, by the maintenance of the required particle size in
the case of dispersions and by the use of surfactants. These
compositions can also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing
agents. Prevention of the action of microorganisms can be
ensured by the inclusion of various antibacterial and antifungal agents such as paraben, chlorobutanol, phenol, sorbic acid
and the like. It can also be desirable to include isotonic agents
such as sugars, sodium chloride and the like. Prolonged
absorption of the injectable pharmaceutical form can be
brought about by the inclusion of agents, such as aluminum
monostearate and gelatin, which delay absorption. Injectable
depot forms are made by forming microencapsule matrices of
the drug in biodegradable polymers such as polylactidepolyglycolide, poly(orthoesters) and poly(anhydrides).
Depending upon the ratio of drug to polymer and the nature of
the particular polymer employed, the rate of drug release can
be controlled. Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions
which are compatible with body tissues. The injectable formulations can be sterilized, for example, by filtration through
a bacterial-retaining filter or by incorporating sterilizing
agents in the form of sterile solid compositions which can be
dissolved or dispersed in sterile water or other sterile injectable media just prior to use. Suitable inert carriers can include
sugars such as lactose. Desirably, at least 95% by weight of
the particles of the active ingredient have an effective particle
size in the range of0.01to10 micrometers.
As used herein, the term "cancer" refers to a proliferative
disorder or disease caused or characterized by the proliferation of cells which have lost susceptibility to normal growth
control. The term "cancer" includes tumors and any other
proliferative disorders. Cancers of the same tissue type originate in the same tissue, and may be divided into different
subtypes based on their biological characteristics. Cancer
includes, but is not limited to, melanoma, leukemia, astocytoma, glioblastoma, lymphoma, glioma, Hodgkins lymphoma, and chronic lymphocyte leukemia. Cancer also
includes, but is not limited to, cancer of the brain, bone,
pancreas, lung, liver, breast, thyroid, ovary, uterus, testis,
pituitary, kidney, stomach, esophagus, anus, and rectum.
As used herein, the term "sensitizing" refers to an
increased sensitivity of a cell or a subject to a treatment, such
as a therapeutic treatment. The term "sensitizing" also refers
to a reduction or decrease in the resistance of a cancer cell or
a subject with cancer in responding to a therapeutic treatment.
An increased sensitivity or a reduced sensitivity to a therapeutic treatment is measured according to a known method in
the art for the particular treatment and methods including, but
not limited to, cell proliferation assays and cell death assays.
The sensitivity or resistance may also be measured in a subject by measuring the tumor size reduction over a period of
time, such as, for example, every 1 to 3 to 6 month for a human
subject and every 2 to 4 to 6 weeks for non-human subject
(e.g., mouse or rat). The sensitivity of a cell or a subject to
treatment can be measured or determined by comparing the
sensitivity of a cell or a subject following administration of a
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CT20p peptide or a composition comprising an effective
amount of a CT20p peptide to the sensitivity of a cell or
subject that has not been administered a CT20p peptide or a
composition comprising an effective amount of a CT20p
peptide.
As used herein, the term "anti-cancer" or "anti-neoplastic"
drug refers to one or more drugs that can be used in conjunction with a CT20p peptide or a composition comprising an
effective amount of a CT20p peptide to treat cancer and/or
aberrant cell growth. Examples of anti-cancer drugs or antineoplastic drugs include, but are not limited to, the following:
Acivicin; Aclarubicin; Acodazole Hydrochloride; AcrQnine;
Adozelesin; Aldesleukin; Altretamine; Ambomycin; Ametantrone Acetate; Aminoglutethimide; Amsacrine; Anastrozole; Anthramycin; Asparaginase; Asperlin; Azacitidine;
Azetepa; Azotomycin; Batimastat; Benzodepa; Bicalutamide; Bisantrene Hydrochloride; Bisnafide Dimesylate;
Bizelesin; Bleomycin Sulfate; Brequinar Sodium; Bropirimine; Busulfan; Cactinomycin; Calusterone; Caracemide;
Carbetimer; Carboplatin; Carmustine; Carubicin Hydrochloride; Carzelesin; Cedefingol; Chlorambucil; Cirolemycin;
Cisplatin; Cladribine; Crisnatol Mesylate; Cyclophosphamide; Cytarabine; Dacarbazine; Dactinomycin; Daunorubicin Hydrochloride; Decitabine; Dexormaplatin; Dezaguanine; Dezaguanine Mesylate; Diaziquone; Docetaxel;
Doxorubicin; Doxorubicin Hydrochloride; Droloxifene;
Droloxifene Citrate; Dromostanolone Propionate; Duazomycin; Edatrexate; Eflomithine Hydrochloride; Elsamitrucin;
Enloplatin; Enpromate; Epipropidine; Epirubicin Hydrochloride; Erbulozole; Esorubicin Hydrochloride; Estramustine; Estramustine Phosphate Sodium; Etanidazole;
Ethiodized Oil I 131; Etoposide; Etoposide Phosphate; Etoprine; Fadrozole Hydrochloride; Fazarabine; Fenretinide;
Floxuridine; Fludarabine Phosphate; Fluorouracil; Fluorocitabine; Fosquidone; Fostriecin Sodium; Gemcitabine; Gemcitabine Hydrochloride; Gold Au 198; Hydroxyurea; Idarubicin Hydrochloride; Ifosfamide; Ilmofosine; Interferon
Alfa-2a; Interferon Alfa-2b; Interferon Alfa-nl; Interferon
Alfa-n3; Interferon Beta-la; Interferon Ganima 1 b; Iproplatin; Irinotecan Hydrochloride; Lanreotide Acetate; Letrozole; Leuprolide Acetate; Liarozole Hydrochloride; Lometrexol Sodium; Lomustine; Losoxantrone Hydrochloride;
Masoprocol; Maytansine; Mechlorethamine Hydrochloride;
Megestrol Acetate; Melengestrol Acetate; Melphalan;
Menogaril; Mercaptopurine; Methotrexate; Methotrexate
Sodium; Metoprine; Meturedepa; Mitindomide; Mitocarcin;
Mitocromin; Mitogillin; Mitomalcin; Mitomycin; Mitosper;
Mitotane; Mitoxantrone Hydrochloride; MycophenolicAcid;
Nocodazole; Nogalamycin; Ormaplatin; Oxisuran; Paclitaxel; Pegaspargase; Peliomycin; Pentamustine; Peplomycin
Sulfate; Perfosfamide; Pipobroman; Piposulfan; Piroxantrone Hydrochloride; Plicamycin; Plomestane; Porfimer
Sodium; Porfiromycin; Prednimustine; Procarbazine Hydrochloride; Puromycin; Puromycin Hydrochloride; Pyrazofurin; Riboprine; Rogletimide; Safingol; Safingol Hydrochloride;
Semustine; Simtrazene;
Sparfosate Sodium;
Sparsomycin; Spirogermanium Hydrochloride; Spiromustine; Spiroplatin; Streptonigrin; Streptozocin; Strontium
Chloride Sr 89; Sulofenur; Talisomycin; Taxane; Taxoid; Tecogalan Sodium; Tegafur; Teloxantrone Hydrochloride;
Temoporfin; Teniposide; Teroxirone; Testolactone; Thiamiprine; Thioguanine; Thiotepa; Tiazofurin; Tirapazamine;
Topotecan Hydrochloride; Toremifene Citrate; Trestolone
Acetate; Triciribine Phosphate; Trimetrexate; Trimetrexate
Glucuronate; Triptorelin; Tubulozole Hydrochloride; Uracil
Mustard; Uredepa; Vapreotide; Verteporfin; Vinblastine Sulfate; Vincristine Sulfate; Vindesine; Vindesine Sulfate; Vine-

pidine Sulfate; Vinglycinate Sulfate; Vinleurosine Sulfate;
Vinorelbine Tartrate; Vinrosidine Sulfate; Vinzolidine Sulfate; Vorozole; Zeniplatin; Zinostatin; Zorubicin Hydrochloride.
Other anti-neoplastic compounds include: 20-epi-1,25
dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALLTK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; anrrubicin; atrsacrine; anagrelide;
anastrozole; andrographolide; angiogenesis inhibitors;
antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein-I; antiandrogen, antiandrogen, pro static
carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DLPTBA; argmme deaminase; asulacrine; atamestane;
atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ABL antagonists; benzochlorins; benzoylstaurosporine; beta lactam derivatives; beta-alethine;
betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; bisaziridinylspermine; bisnafide; bistratene
A; bizelesin; breflate; bropirimine; budotitane; buthionine
sulfoximine; calcipotriol; calphostin C; camptothecin derivatives; canarypox IL-2; capecitabine; carboxamide-aminotriazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors
(ICOS); castanospermine; cecropin B; cetrorelix; chlorins;
chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin;
cladribine; clomifene analogues; clotrimazole; collismycin
A; collismycin B; combretastatin A4; combretastatin analogue; conagenin; crambescidin 816; crisnatol; cryptophycin
8; cryptophycin A derivatives; curacin A; cyclopentanthraquinones; cycloplatam; cypemycin; cytarabine ocfosfate;
cytolytic factor; cytostatin; dacliximab; decitabine; dehydrodidenmin B; deslorelin; dexifosfamide; dexrazoxane;
dexverapamil; diaziquone; didenmin B; didox; diethylnorspermine; dihydro-5-azacytidine; dihydrotaxol, 9-; dioxamycin; diphenyl spiromustine; docosanol; dolasetron; doxifluridine; droloxifene; dronabinol; duocannycin SA; ebselen;
ecomustine; edelfosine; edrecolomab; eflornithine; elemene;
emitefur; epirubicin; epristeride; estramustine analogue;
estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole; fazarabine; fenretinide; filgrastim; finasteride; flavopiridol; flezelastine; fluasterone; fludarabine;
fluorodaunorunicin hydrochloride;
forfenimex; formestane; fostriecin; fotemustine; gadolinium
texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; heregulin; hexamethylene bisacetamide; hypericin;
ibandronic acid; idarubicin; idoxifene; idramantone; ilmofosine; ilomastat; imidazoacridones; imiquimod; immunostimulant peptides; insulin-like growth factor-I receptor
inhibitor; interferon agonists; interferons; interleukins;
iobenguane; iododoxorubicin; 4-ipomeanol; irinotecan;
iroplact; irsogladine; isobengazole; isohomohalicondrin B;
itasetron; jasplakinolide; kahalalide F; lamellarin-N triacetate; lanreotide; leinamycin; lenograstim; lentinan sulfate;
leptolstatin; letrozole; leukemia inhibiting factor; leukocyte
alpha interferon; leuprolide+estrogen+progesterone; leuprorelin; levamisole; liarozole; linear polyamine analogue; lipophilic disaccharide peptide; lipophilic platinum compounds;
lissoclinamide 7; lobaplatin; lombricine; lometrexol;
lonidamine; losoxantrone; lovastatin; loxoribine; lurtotecan;
lutetium texaphyrin; lysofylline; lytic peptides; maitansine;
mannostatin A; marimastat; masoprocol; maspin; matrilysin
inhibitors; matrix metalloproteinase inhibitors; menogaril;
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merbarone; meterelin; methioninase; metoclopramide; MIF
inhibitor; mifepristone; miltefosine; mirimostim; mismatched double stranded RNA; mitoguazone; mitolactol;
mitomycin analogues; mitonafide; mitotoxin fibroblast
growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotrophin; monophosphoryl lipid A+myobacterium cell wall sk;
mopidamol; multiple drug resistance genie inhibitor; multiple tumor suppressor I-based therapy; mustard anticancer
agent; mycaperoxide B; mycobacterial cell wall extract;
myriaporone; N-acetyldinaline; N-substituted benzamides;
nafarelin; nagrestip; naloxone+pentazocine; napavin; naphterpin; nartograstim; nedaplatin; nemorubicin; neridronic
acid; neutral endopeptidase; nilutamide; nisamycin; nitric
oxide modulators; nitroxide antioxidant; nitrullyn; 06-benzylguanine; octreotide; okicenone; oligonucleotides;
onapristone; ondansetron; oracin; oral cytokine inducer;
ormaplatin; osaterone; oxaliplatin; oxaunomycin; paclitaxel
analogues; paclitaxel derivatives; palauamine; palmitoylrhizoxin; pamidronic acid; panaxytriol; panomifene; parabactin; pazelliptine; pegaspargase; peldesine; pentosan
polysulfate sodium; pentostatin; pentrozole; perflubron; perfosfamide; perillyl alcohol; phenazinomycin; phenylacetate;
phosphatase inhibitors; picibanil; pilocarpine hydrochloride;
pirarubicin; piritrexim; placetin A; placetin B; plasminogen
activator inhibitor; platinum complex; platinum compounds;
platinum-triamine complex; porfimer sodium; porfiromycin;
propyl bis-acridone; prostaglandin 12; proteasome inhibitors;
protein A-based immune modulator; protein kinase C inhibitors; microalgal; protein tyrosine phosphatase inhibitors;
purine nucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylene
conjugate; rafantagonists; raltitrexed; ramosetron; ras farnesyl protein transferase inhibitors; ras inhibitors; ras-GAP
inhibitor; retelliptine demethylated; rhenium Re 186 etidronate; rhizoxin; ribozymes; RII retinamide; rogletimide;
rohitukine; romurtide; roquinimex; rubiginone Bl; ruboxyl;
safingol; saintopin; SarCNU; sarcophytol A; sargramostim;
Sdi 1 mimetics; semustine; senescence derived inhibitor 1;
sense oligonucleotides; signal transduction inhibitors; signal
transduction modulators; single chain antigen binding protein; sizofuran; sobuzoxane; sodium borocaptate; sodium
phenylacetate; solverol; somatomedin binding protein; sonermin; sparfosic acid; spicamycin D; spiromustine; splenopentin; spongistatin 1; squalamine; stem cell inhibitor; stemcell division inhibitors; stipiamide; stromelysin inhibitors;
sulfmosine; superactive vasoactive intestinal peptide antagonist; suradista; suramin; swainsonine; synthetic glycosaminoglycans; tallimustine; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium;
telomerase inhibitors; temoporfin; temozolomide; teniposide; tetrachlorodecaoxide; tetrazomine; thaliblastine; thalidomide; thiocoraline; thrombopoietin; thrombopoietin
mimetic; thymalfasin; thymopoietin receptor agonist; thymotrinan; thyroid stimulating hormone; tin ethyl etiopurpurin; tirapazamine; titanocene dichloride; topotecan; topsentin; toremifene; totipotent stem cell factor; translation
inhibitors; tretinoin; triacetyluridine; triciribine; trimetrexate; triptorelin; tropisetron; turosteride; tyrosine kinase
inhibitors; tyrphostins; UBC inhibitors; ubenimex; urogenita! sinus-derived growth inhibitory factor; urokinase receptor
antagonists; vapreotide; variolin B; vector system, erythrocyte gene therapy; velaresol; veramine; verdins; verteporfin;
vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone; zeniplatin; zilascorb; zinostatin stimalamer.
As used herein, radiosensitizers make a cancer cell more
likely to be damaged. Radiosensitizers enhance the sensitiv-

ity of cancer cells and/or a tumor to iomzmg radiation,
thereby increasing the efficacy of radiotherapy. Examples of
radiosensitizers include gemcitabine, 5-fluorouracil, pentoxifylline, and vinorelbine.
The majority of chemotherapeutic drugs can be divided in
to: alkylating agents (e.g., cisplatin, carboplatin, oxaliplatin,
mechloethamine, cyclophosphamide, chlorambucil, anti-metabolites (e.g., azathioprine, mercaptopurine ), anthracyclines, plant alkaloids and terpenoids (e.g., vinca alkaloids
(e.g., vincristine, vinblastine, vinorelbine, vindesine, and
podophyllotoxin) and taxanes (e.g., paclitaxel and docetaxel ), topoisomerase inhibitors (e.g., irinotecan, topotecan,
amsacrine, etoposide, etoposide phosphate, and teniposide),
monoclonal antibodies (e.g., trastuzumab, cetuximab, rituximab, bevacizumab ), other antitumour agents (e.g., dactinomycin), and hormonal therapy (e.g., steroids such as dexamethasone ),
finasteride,
aromatase
inhibitors,
and
gonadotropin-releasing hormone agonists).
Disclosed are the components to be used to prepare a
composition of the invention as well as the compositions
themselves to be used within the methods disclosed herein.
These and other materials are disclosed herein, and it is understood that when combinations, subsets, interactions, groups,
etc. of these materials are disclosed that while specific reference of each various individual and collective combinations
and permutation of these compounds can not be explicitly
disclosed, each is specifically contemplated and described
herein. For example, if a particular compound is disclosed
and discussed and a number of modifications that can be made
to a number of molecules including the compounds are discussed, specifically contemplated is each and every combination and permutation of the compound and the modifications that are possible unless specifically indicated to the
contrary. Thus, if a class of molecules A, B, and C are disclosed as well as a class of molecules D, E, and F and an
example of a combination molecule, A-D is disclosed, then
even if each is not individually recited each is individually
and collectively contemplated meaning combinations, A-E,
A-F, B-D, B-E, B-F, C-D, C-E, and C-F are considered disclosed. Likewise, any subset or combination of these is also
disclosed. Thus, for example, the sub-group of A-E, B-F, and
C-E would be considered disclosed. This concept applies to
all aspects of this application including, but not limited to,
steps in methods of making and using the compositions of the
invention. Thus, if there are a variety of additional steps that
can be performed it is understood that each of these additional
steps can be performed with any specific embodiment or
combination of embodiments of the methods of the invention.
All patents, patent applications, and other scientific or
technical writings referred to anywhere herein are incorporated by reference in their entirety. The invention illustratively described herein suitably can be practiced in the
absence of any element or elements, limitation or limitations
that are not specifically disclosed herein. Thus, for example,
in each instance herein any of the terms "comprising", "consisting essentially of, and "consisting of can be replaced with
either of the other two terms, while retaining their ordinary
meanings. The terms and expressions which have been
employed are used as terms of description and not oflimitation, and there is no intention that in the use of such terms and
expressions of excluding any equivalents of the features
shown and described or portions thereof, but it is recognized
that various modifications are possible within the scope of the
invention claimed. Thus, it should be understood that
although the present invention has been specifically disclosed
by embodiments, optional features, modification and variation of the concepts herein disclosed can be resorted to by
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those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as
defined by the description and the appended claims.

haker et al., 2011 ). The Protea Tuner IRES2 system
(Clontech) also had the marker protein GFP downstream to
the internal ribosome entry sequence (IRES) and was translated independently of the DD-tagged protein. Cells were
transiently transfected using the TransIT-LTl transfection
reagent (Minis) for 24 hours and microscopically assayed for
GFP expression. Expression of DD-tagged proteins was
induced for 4-5 hours by adding 500 nM of Shield (Clontech).
MDA-MB-231 cells were transiently transfected with
pcDNA-Bcl2 (or as control pEGFP (Clontech)) using the
TransIT-LTl transfectionreagent (Minis). To assess transfection efficiency, cells were assayed microscopically for EGFP
expression. To assess Bcl-2 expression, cells lysates were
immunoblotted.
d. Detection of Mitochondrial Translocation
Mitochondrial and cytosolic proteins were isolated using a
mitochondrial enrichment kit (Pierce). Western blots were
run using 12-15% SDS-PAGE gels and PVDF membranes
and probed with the following primary antibodies: 16Bl2
anti-HA mouse monoclonal (Covance) for HA-tagged Bax;
631073Anti-DD monoclonal (Clontech) for DD-Bax; N-20
(Santa Cruz) for endogenous Bax; Ab-2 (Fitzgerald) for prohibitin; C20 (MAPK) (Santa Cruz) for p38 MAP kinase; and
rabbit polyclonal for Bcl-2 (Santa Cruz). The appropriate
secondary antibodies conjugated to horseradish peroxidase
(HRP) was then used and visualized with enhanced chemiluminescence kit (Pierce). Molecular weight markers (SeeB!ue
Plus 2 (Invitrogen)) were used to approximate the position of
protein bands in blots.
e. Co-Localization of Mitochondrial Proteins
To determine whether expression of DD-tagged Bax C-terminal peptides co-localized with mitochondria, Bax+/+ HCT116 cells and Bax- 1- HCT-116 cells were cultured for 24
hours on coverslips pretreated with laminin. The DD-Bax
C-terminal WT peptide and DD-Bax C-terminal EE, LL, and
RR mutations constructs were transfected into the cells using
Minis LT-1 reagent according manufacturer's protocol. After
24 hours, expression of the transfected peptides was induced
by the addition of shield 1 for 4 hrs. Cells were fixed with 2%
w/v formaldehyde/PBS for 15 minutes and permeabilized
using 0.05% Triton X-100/PBS for 15 minutes. After washing, cells were incubated with primary antibodies HSP60
(H-300, Santa Cruz) and DD monoclonal antibody for 1 hour
at room temperature, which was followed by incubation with
secondary anti-rabbit-Cy3 (81-6115, Invitrogen) and antimouse-Texas red (715076020, Jackson Immunoresearch) for
30 minutes. After the final wash, cells were mounted with
gel/mount medium (Mo!, Biomeda) and images were
acquired with UltraView (PerkinElmer) microscopy with a
plan-apochromat 63x/l .4 oil objective. The scanned images
were processed and Pearson's correlation coefficients determined using Velocity Version 5.5 (Perkin Elmer).
f. Generation and Expression of EGFP-CT20p Peptide
Fusion Constructs
To generate the EGFP-CT20p peptide fusion proteins,
primers incorporating the CT (amino acids 173-192) of Bax
with mutations targeting Kl 89/Kl 90 (Table 1) were used to
amplify EGFP from the template pEGFP (Clontech). The
PCR insert was cloned into pcDNA5/FRT/TO as previously
above. HCT-116 cells were transiently transfected using the
TransIT-LTl transfection reagent (Minis) and cells assayed
microscopically for EGFP expression up to 12 hours later.
g. Confocal Imaging of Live Cells
Images were acquired through a PerkinElmer UltraView
spinning disc confocal system with AxioObserver.Zl stand
(Carl Zeiss) in a humidity and temperature-controlled chamber (LiveCell) with cells cultured on MatTek plates (MatTek

0004. Experimental
The following examples are put forth so as to provide those
of ordinary skill in the art with a complete disclosure and
description of how the compounds, compositions, articles,
devices and/or methods claimed herein are made and evaluated, and are intended to be purely exemplary of the invention
and are not intended to limit the scope of what the inventors
regard as their invention. However, those of skill in the art
should, in light of the present disclosure, appreciate that many
changes can be made in the specific embodiments which are
disclosed and still obtain a like or similar result without
departing from the spirit and scope of the invention.
Efforts have been made to ensure accuracy with respect to
numbers (e.g., amounts, temperature, etc.), but some errors
and deviations should be accounted for. Unless indicated
otherwise, parts are parts by weight, temperature is in ° C. or
is at ambient temperature, and pressure is at or near atmospheric.
1. General Experiments
a. Establishment of Cell Lines
The Flp-In T-REx-293 cell line (Invitrogen) stably
expressed the lacZ-Zeocin fusion gene and Tet repressor. The
293 line was maintained in Dulbecco's Modified Eagle
Medium (DMEM), 10% fetal bovine serum (FBS) (tetracycline-reduced), 2 mM L-glutamine and 1% Penicillin-Streptomycin. The HCT-116 Bax_;_ and Bax+/+ colorectal cancer
cell lines (Zhang et al., 2000) were maintained in McCoy's
SA media, 10% FBS, and 1% Penicillin-Streptomycin. The
breast cancer cell lines, MCF-7 and MCB-MD-231 (ATCC),
were maintained in DMEM, 10% FBS, and 1% PenicillinStreptomycin. MCF-7 cells were supplemented with 1%
L-Glutamine every 15 days. Early passages of all cell lines
were frozen as stocks at time of receipt. Cell lines were used
at less than 10 passages from stocks.
b. Generation of the CT20 Bax Peptide
The CT20p peptide (Ac-VITFVAGVLTASLTIWKKMGNH2) (Biopeptide Co., Inc.) (SEQ ID NO: 53) was commercially synthesized at >98% purity.
C. Generation of Plasmids for Muta genesis and Transfection
For inducible expression of Bax, the Flp-In T-REx System
(Invitrogen) was utilized according to the manufacturer's
protocol. Briefly, PCR-directed mutagenesis of Kl 89/Kl 90
was performed using HA-tagged primer sets (Table 1). Bax
constructs were amplified from pEGFP-Bax, digested with
EcoRV, and cloned into the plasmid pcDNA5/FRT/TO, which
undergoes DNA recombination at the Flp Recombination
Target (FRT) site when co-expressed with the Flp recombinase pOG44 plasmid. Constructs were confirmed by
sequencing. Fu gene transfection reagent (Roche) was used to
co-transfect plasmids at a ratio of 9:1. Stable Flp-In T-REx
expression cell lines were selected for Blasticidin resistance
(10 µg/mL ), Hygromycin resistance (100 µg/mL) and Zeocin
sensitivity (200 µg/mL). Bax expression was induced with 1
µg/mL tetracycline. Cells were assayed after 24 hours of
induction. See Table 1 for sequences and primers used herein.
To generate the Destabilization Domain (DD)-tagged Bax
CT (amino acids 173-192) fusion proteins with Kl89/Kl90
(wild-type) or EE, LL, and RR mutations, primers (Table 1)
were annealed and ligated into the Protea Tuner vector (Clantech) digested by EcoRI and BamHI. Generation of DDtagged, full-length WT Bax was previously described (Boo-
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Corporation). Post-acquisition snapshots were taken from
time-lapse movies at time points indicated in the figures. For
EGFP-CT20 Bax fusion proteins, time-lapse movies were
initiated two hours after transfection and images acquired
through 12 hours of expression using a Plan-Apochromat 1Ox
objective. For DD-CT20 Bax fusion proteins, cells were incubated with 1 nM MitoTracker Red 580 for 30 minutes prior to
imaging. Time-lapse movies were recorded for up to 12 hours
using a Plan-Apochromat 63x Oil DIC objective.
Visualization of the uptake and effects of the fluorescent
dye (DiI)-loaded nanoparticles in HCT-116, MCF-7, and
MDA-MD-231 cells was observed using a !Ox air objective
with a numerical aperture of0.3, using ex/em of 514/587. All
cells were loaded with MitoTracker. Visualization of the
HCT-116 cell lines was observed using Plan-Apochromat
63x Oil objective. MCF-7 and MDA-MB-231 images were
captured using Plan-Apochromat 40x Oil objective. All timelapse images were generated in 2D by capturing 6 time points
per hour for 24 hours of the same field.
h. Treatments and Detection of Apoptotic Cells by Flow
Cytometry
HCT-116, MCF-7, or MDA-MB-231 cells were collected
at a final concentration of 1x10 6 cells/mL and assayed using
the SYTOX® AADvanced™ dead cell stain solution (Invitrogen). Cells were analyzed using the BD FACSCanto flow
cytometer. SYTOX® AADvanced™ was visualized at 488
nm and emissions collected at 695 nm. Analysis of data was
done using FSC Express software (DeNovo). Membrane
asymmetry was assessed using the Violet Ratiometric Membrane Asymmetry Probe/Dead Cell Apoptosis Kit (Invitrogen) according to the manufacturer's protocol.
To evaluate apoptosis, cells were pre-treated with 100 µM
of the pan-caspase inhibitor Z-VAD-fmk (EMD Biosciences)
or transiently transfected with Bcl-2, then treated with either
CT20/nanoparticles or cisplatin (CDDP) alone or in combination as indicated in figure legends. Following treatment,
cells were analyzed for cell death and membrane asymmetry.
i. Synthesis of Polymeric Nanoparticles Encapsulating the
Bax CT20 Bax Peptide
The Bax CT20p peptide was encapsulated into hyperbranched polymeric (HBPE) nanoparticles following a previously reported method (Santra et al., 2010). A fluorescent
dye (DiI) was co-encapsulated with the peptide. In brief, 1.0
µL, ofDiI dye (10 µg/µL) and36 µL, ofCT20p peptide (0.05
µg/µL) solution in 250 µL, ofDMSO were mixed in 250 µL of
a DMSO solution containing the HBPE polymer (12 mg) for
a ratio of -0.15 µg peptide: 1 mg nanoparticles. The resulting
polymer-Dil/Bax mixture in DMSO was added to deionized
water (2.5 mL) to form the HBPE (Bax CT20/DiI) nanoparticles. The resulting nanoparticles were purified using a
PD-10 column and dialyzed (MWCO 6-8K) against PBS
(pH=7.4). Dynamic light scattering and zeta potential analysis of the nanoparticle reveals a size diameter of 88±2 nm and
zeta potential of -54.5 mV.
j. Synthesis of Aminated Polymeric Nanoparticles Encapsulating the CT20 Bax Peptide
The HBPE nanoparticles contain functional carboxylic
groups on their surface that resulted in a negative charge. To
introduce a positively charged surface, the nanoparticles were
aminated using water-soluble carbodiimide chemistry [EDC:
1-ethy1-3-(3-dimethylamino-propy l)carbodiimide
hydrochloride and NHS: N-hydroxysuccinimide chemistry], following a previously reported method (Santra et al., 2010).
Briefly, to a solution ofHBPE (Bax CT20/DiI) nanoparticles
(1.0 mmol) in PBS (pH=7.4), a solution ofEDC (10 mmol)
and NHS (10 mmol) in MES buffer (pH=6.0) was added.
Afterwards, ethylenediamine (10 mmol) in DMSO was added

to obtain aminated DiI/Bax co-encapsulation polymeric
nanoparticles (PNPs ), which were purified and dialyzed.
Dynamic light scattering and zeta potential analysis of the
nanoparticle reveals a nanoparticle size diameter or 91 ±3 nm
and zeta potential of+ 10.3 m V. All nanoparticles were stored
at 4° C. A final working concentration of350 pM was determined by testing the toxicity of 7 nM, 1.4 nM, 0.7 nM, and
0.35 nM using HCT-116+1+ cells.
k. Determination of Calcein Release
Calcein release from artificial membranes was measured
on a JASCO 810 spectropolarimeter (Jasco Inc.) with a Peltier
water cooled thermostat and a photomultiplier tube mounted
at 90 degrees for fluorescence measurements. Large unilamellar vesicles (LUVs) were prepared with the following
modifications: Lipids (Avanti Polar Lipids) in chloroform
were mixed in the following molar ratios: 52.5% l-palmitoyl2-oleyl-sn-glycero-3-phosphatidylcholine (POPC), 21 %
1-palmitoy1-2-oleyl-sn-glycero-3-phosphatidy lethanolamine (POPE), 13% bovine liver L-a phosphatidylinositol
(PI), 10% cholesterol and 3.5% l-palmitoyl-2-oleyl-sn-glycero-3-phosphatidylglycerol (POPG). These rations mimicked the outer mitochondrial membrane. After removing
chloroform and desiccating, the dried lipid film was resuspended in 50 mM HEPES, pH 7, supplemented with 110 mM
NaCl and 80 mM calcein and extruded with Avanti's mini
extruder (Alabaster, Ala.). External calcein was removed by
gel filtration through a 1.5x50 cm Econo-Colunm (Bio-Rad)
freshly packed with Sephadex 50 (GE Healthcare). CT20 Bax
peptides were added at concentrations equivalent to those
used with cells in culture. Calcein fluorescence was excited at
495 nm and emission spectra recorded between 510 and 550
nm (excitation/emission slits: 10/3 nm). Samples were maintained at 37° C. and a final measurement taken at 24 hours.
Maximum calcein release was obtained by the addition of
Triton x 100 (0.1% final concentration) to calcein loaded
LUVs without nanoparticles that had had been incubated at
37° C. for 24 hours after the addition of 10 µL DMSO.
1. In Vivo Experiments
One to two million MBA-MD-231 cells were harvested
from culture and injected subcutaneously into the right and
left flanks of 16 female nude mice (nu/nu, Charles River).
After 2-3 weeks, tumor volume and growth was assessed by
ultrasound (VisualSonics Vevo 2100). Mice with tumors were
injected intratumorally with PBS, unloaded polymeric nanoparticles, or CT20 Bax peptide-loaded polymeric nanoparticles at 4x the concentrations described above. Injections
were performed twice over a 4-5 day period. Mice were
observed 0-5 days post-treatments and tumor volume
assessed by ultrasound.
2. C-Terminal a9 Helix of Bax Enables Membrane Binding and Permeabilization
To develop a novel anti-cancer agent that could be used to
sensitize cancer cells to treatment, the death-inducing activity
of Bax was examined. The protein's C-terminal domain was
a point of focus because of its putative membrane-binding
properties (Ausili et al., 2008; Martinez-Senac et al., 2001;
Nechushtan et al., 1999; Schinzel et al., 2004). Mutagenesis
of the C-terminus of full-length Bax was performed (Table 2).
As the constitutive expression of N-terminal-tagged Bax
induced spontaneous cell death. To avoid this, full-length
HA-tagged Bax was expressed in stably transfected Flp-In
T-REx 293 cells. Bax constructs were integrated into the
genome at a single FRT (recombination) site and the levels of
Bax expression in these isogenic cell lines did not cause
apoptosis. These experiments determined the role of the
C-terminus and amino acids Kl 89/Kl 90 in the localization of
Bax under normal cellular conditions.
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TABLE2

lysines (K189/Kl90 in the full-length protein) were
exchanged with leucine (LL) or aspartic acid (EE), did not
cause calcein release. This indicated that the original lysines
at positions 189 and 190 were required for optimal membrane
permeabilization. CT20 Bax or mutant CT20-LL peptides
stabilized the lipid membranes and impaired the maximal
release of calcein upon treatment with detergent (FIG. lC).
However, this did not occur with the CT20-EE peptide, indicating that the amino acid sequence of the peptide dictated the
nature of the interaction with lipid membranes. These data
demonstrated that the CT20 peptide bound to lipid membranes and caused the release of vesicular contents, and further demonstrated that the CT20p peptide added rigidity or
structure to the lipid membranes.
3. Expression of the CT20p Peptide Induces Cell Death
Having established the importance of the C-terminal
domain of Bax in the intracellular localization of the protein
and demonstrated the membrane-binding and permeabilization properties of the CT20 Bax peptide, the capacity of the
CT20p peptide to induce cell death was next evaluated. Specifically, whether the CT20p peptide had cytotoxic properties
based on its capacity to associate with lipid membranes of
organelles like mitochondria was assessed. The CT20p peptide domain was fused to a short destabilization domain (DD)
for detection and inducible expression. The CT20p peptide
fused to DD (DD-CT20) was inducibly expressed in HCT116 cells and peptide localization and induction of cell death
was examined. For a control, the action of the DD-CT20 (KK
and EE, LL and RR mutants) peptides to DD-tagged fulllength (FL) Bax was compared. Induced expression ofDDFL Bax did not cause cell death in the absence of apoptotic
stimuli.
Gene expression was induced for four hours after previous
transfection of cells with DD-FL Bax or DD-CT20 peptide
constructs. Constitutive GFP expression on the bi-cistronic
plasmid was controlled by an IRES element and used to detect
transfected cells. The mitochondrial translocation of DDtagged Bax full-length (FL-Bax) and DD-tagged CT20 peptides, wild-type and EE, LL and RR mutants, was examined in
Bax+!+ HCT-116 cells by immunoblot.As shown in FIG. 2A,
most of the DD-tagged FL Bax was found in cytosolic
extracts. A fraction of DD-FL-Bax was also found in mitochondria extracts. The small 15-16 kDbandofDD-CT20KK
peptides or DD-CT20 mutant peptides (EE, LL, and RR
(fainter band)) was detected in mitochondrial extracts, indicating that the DD-CT20 peptides were targeting mitochondria.
Expression of DD-CT20 Bax also caused the mitochondrial translocation of a small amount endogenous Bax (FIG.
2A). Data are representative of two independent assays. In
FIG. 2A, endogenous Bax was probed with anti-Bax antibody. p38 MAPK and prohibitin indicated cytosolic and
mitochondrial content, respectively. DD-fusions were
detected with an anti-DD antibody. Controls were cells transfected with empty vector or untransfected. Images from fulllength blots were cropped for concise presentation.
These results were confirmed by immunofluorescence
(FIG. 7). In FIG. 7A, cells were fixed and double-stained with
primary antibodies for HSP60 and DD. The fixed cells were
then incubated with secondary anti-rabbit-Cy3 and antimouse-Texas red. The overlay appears as white. In FIG. 7B,
the bar graphs indicate the quantitative assay of co-localization of DD-tagged peptides to mitochondria. The measurements are represented by three samples.
Experiments attaching the CT20 peptides to EGFP confirmed the findings that fusion of the CT20p peptide could
confer membrane binding properties (FIGS. SA and SB). In

Effect of Kl 89/Kl 90 Mutations on Bax Intracellular Localization.
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Localization of full-length, wild-type (WT) Bax (Bax-KK)
was distributed among cytosolic and mitochondrial lysates
(FIG. lA). Specifically, mitochondrial translocation of HAtagged wild type Bax (Bax-KK) and Kl89/Kl90 mutants,
expressed in 293 cells using the Flp-In T-Rex system, was
examined by immunoblot. p38 MAPK and prohibitin were
blotted for cytosolic and mitochondrial content, respectively.
Data are representative of five independent assays. Images
from full-length blots were cropped for concise presentation.
N-terminal-deleted Bax (Bax-ANT) was localized primarily
to mitochondria while the C-terminal-deleted Bax (BaxACT) was retained in the cytosol. These data indicate the role
of the N- and C-terminal domains in Bax localization (FIG.
lA).
Substitution of Kl 89/Kl 90 with negatively charged residues, aspartic acid (D) or glutamic acid (E), resulted in the
cytosolic retention of Bax (Bax-DD, Bax-EE) (FIG. lB).
Substitution of Kl 89/Kl 90 with positively charged arginine
(R) (Bax-RR) led to mitochondrial localization (FIG. lB).
Substitution of Kl 89/Kl 90 with a polar amino acid,
glutamine (Q) (Bax-QQ), led to less mitochondrial Bax,
when compared Bax-KK and Bax-RR (FIGS. lA and lB).
Substitution of Kl 89/Kl90 with the hydrophobic amino acid
leucine (L) (Bax-LL) resulted in mitochondrial association
(FIG. lA). Mutation of Kl89 (Bax-EK) also rendered Bax
cytosolic, which was not observed by mutation of Kl 90 (BaxKMGK) (FIGS. lA and lB, Table 2). These results demonstrated that the C-terminus of Bax, and Kl 89/Kl 90, modulated the association of the full-length protein with
mitochondria.
Analysis of the effects of mutations of Kl 89/Kl 90 in fulllength Bax indicated that the C-terminal domain was a preferred region from which to fashion a membrane-binding and
possibly a membrane-permeabilizing peptide. Using a commercially synthesized peptide composed of the last twenty
amino acids (172-192) of the C-terminus of Bax (CT20), the
ability of CT20p peptide to insert and permeabilize lipid
membranes was examined. Liposomes contained phospholipids that composed the mitochondrial outer membrane and
were loaded with calcein. FIG. lC demonstrates that the
CT20p peptide inserted itself into mitochondrial-like lipid
vesicles and caused the release of calcein. In FIG. lC, the red
lines indicate maximal release of calcein with Triton X-100.
The blue lines indicate treatment with DMSO and the green
lines (except for control) indicate treatment with CT20 Bax
peptides. A mutant CT20 Bax peptide, in which the terminal
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FIGS. SA and SB, the mitochondrial translocation ofEGFPtagged with Bax CT (EGFP-KK) and K189/K190 mutants
was examined in Bax+/+ HCT-116 cells (A) and Bax- 1- HCT116 cells (B) by immunoblot. p38 MAPK and Prohibitin were
assessed for cytosolic and mitochondrial content, respectively. Control sample are untransfected cells. Data are representative of five independent assays. Images from fulllength blots were cropped for concise presentation.
In FIGS. SC and SD, Bax+i+ HCT-116 cells and Bax_;_
HCT-116 cells, respectively, were transfected with the EGFPKK or K189/K190 mutants. Time-lapse movies were
acquired with a 63x Oil objective. For each sample, three
different fields of view were acquired. Images shown are
snapshots taken at specified time points.
The toxicity of DD-CT20 KK peptide was shown when
expression was induced inHCT-116 cells (FIG. 2B for Bax+/+
cells and FIG. 2C for Bax- 1- cells). For each sample, three
different fields of view were acquired. Images are representative "snapshots" of four independent experiments. Within
five hours of gene induction, the DD-CT20 KK peptide
caused membrane perturbations and the death of Bax-containing cells. Similar results were observed with the other
forms ofDD-CT20 (EE, LL and RR) peptides, although the
death kinetics varied depending on the mutation (LL and RR
mutants took longer to cause death) (FIG. 2B, 5 hours; insets
in FIG. 2B were increased 3-fold). Moreover, Bax deficiency
did not impair the lethality of the CT20 Bax peptide. This was
observed by expressing DD-CT20 KK in Bax_;_ HCT 116
cells, which caused cell death detectable by 3-5 hours (FIG.
2C, 12 hours). DD-CT20 EE caused membrane disturbances
by 1 hour of induction and death by 3 hours. This was followed by DD-CT20 RR, with loss of membrane integrity
observed within 3 hours, and DD-CT20 LL causing membrane fluctuations by 5 hours and death by 11 or 12 hours
(FIG. 2C). While mutation of the C-terminal lysines did not
block mitochondrial translocation (FIG. 2A) or prevent cell
death, it did alter the timeframe in which death occurred.
These finding were confirmed with multiple similar experiments, which accounted for differences in transfection efficiency and expression of individual constructs. The data indicate that the C-terminal lysines were needed to "fine tune" the
interaction of the CT20 peptide with mitochondrial membranes, altering its capacity to induce cell death. (See FIG. lC
showing that CT20 peptides (WT and mutants) associated
with lipid membranes, which affected membrane rigidity, but
that only the CT20 WT (containing Kl 89/Kl 90) enabled the
maximal release of calcein from loaded vesicles).
4. Delivery of the CT20 Peptide Using Polymeric Nanoparticles Kills Cancer Cells
To determine whether the CT20p peptide could directly kill
cancer cells, the CT20 wild type peptide was encapsulated in
polymeric nanoparticles. As the CT20p peptide is amphipathic, it can be encapsulated within the hydrophobic pockets
of aliphatic polymeric nanoparticles. FIG. 3A shows a schematic representation of the three dimensional structure of
aliphatic hyperbranched nanoparticles, in which DiI (fluorescent dye) and commercially synthesized CT20 Bax peptides
were encapsulated into positively charged, aminated (AM) or
negatively charged, carboxylated (COOH) nanoparticles
(Santra et al., 2010). To verify that the nanoparticles would
not release the CT20 peptide at neutral pH, calcein loaded
liposomes were prepared. While the CT20p peptide alone
(350 pM) did induce the release of calcein (as shown in FIG.
lC), nanoparticles loaded with CT20 peptide (350 pM) did
not induce the release of calcein from liposomes, indicating
that the nanoparticles were intact at pH 7 (FIG. 9).

In FIG. 9, a calcein release assay was performed with
calcein loaded lipid vesicles prepared with the composition of
the mitochondrial membrane. Calcein release was measured
as fluorescence. Controls were calcein release achieved with
CT20p peptide alone and maximum calcein release obtained
upon addition of Triton xlOO. A representative experiment of
two independent experiments is shown. This confirmed that
cargo is released from nanoparticles only by intracellular
esterases or acidic pH (Santra et al., 2010).
The uptake ofDiI-loaded nanoparticles and effect upon the
viability of HCT-116 cells was evaluated. HCT-116 cells
were treated with nanoparticles loaded with DiI or DiI +CT20
peptide (0.07 nM) for24 hours. FIG. 3B shows thatHCT-116
cells took up nanoparticles, more so for the Bax-deficient
cells that were highly glycolytic (Boohaker et al., 2011 ).
While treatment of HCT-116 cells with nanoparticles (unloaded) did not cause significant cell death (FIG. 3B), treatment of HCT-116 cells with CT20 peptide-loaded nanoparticles at a concentration of700 pM (or 0.07 nM), caused rapid
cell death (FIG. 3B). For each sample, three different fields of
view were acquired. Images are representative "snapshots" of
two independent experiments.
To demonstrate that nanoparticles alone (i.e., without the
CT20 peptide) did not cause death, a DNA-binding dye (Sytox) was utilized to detect membrane rupture of dead cells.
FIG. 3C shows that minimal (Bax+/+ HCT-116) to no (Bax-1HCT-116) cell death was detected upon addition of DiIloaded nanoparticles (5 µg, 10 µg or 15 µg) as compared to the
positive control (dead cells). To minimize off-target effects,
all subsequent experiments were performed at the lowest dose
of the CT20 peptide (350 pM)-nanoparticles (2.5 µg).
To visualize the effect of CT20 Bax peptide-nanoparticles
upon mitochondria, Bax-containing or Bax-deficient HCT116 cells were stained with Mitotracker and imaged live cells.
Bax+!+ (FIG. 4A) and Bax- 1- (FIG. 4B) HCT-116 cells were
treated with AM- or COOH-nanoparticles loaded with CT20
peptide (350 pM) for 24 hours. To visualize mitochondria,
cells were treated with MitoTracker Red 580 and time-lapse
movies were acquired using a 63x Oil objective. FIGS. 4A
and 4B show "snapshots" at 0, 12, and 24 hour time points.
These snapshots revealed changes in cell morphology, which
changes included disruption of mitochondria (reduced or
faint Mitotracker staining), as well as cell shrinkage and
membrane perturbations, which were indicative of cell death.
Similarly, HCT-116 cells were treated with nanoparticles
loaded with CT20 peptide (350 pM). Cell death was measured and the loss of membrane integrity was detected within
three hours of treatment with CT20 Bax peptide-nanoparticles (FIG. 4C). Both AM-nanoparticles and COOH-nanoparticles containing CT20p peptide were efficacious in initiating cell death (FIG. 4C), although the COOH-nanoparticle
formulation appeared more effective. These results coupled
with those in FIG. 2 indicated that the death-inducing activity
of the CT20p peptide was independent of endogenous Bax.
With respect to FIGS. 4A-C, three different fields of view
were acquired for each sample. Images are representative
"snapshots" of three independent experiments.
Whether the CT20 peptide was able to kill the breast cancer
cells, MCF-7 and MDA-MB-231, was examined. As shown
in FIG. SA, morphological changes such as cell shrinkage and
membrane perturbations in MCF-7 cells following treatment
for 24 hours with AM- or COOH-nanoparticles containing
the CT20p peptide (350 pM) were observed. For each sample,
three different fields of view were acquired. Images are representative "snapshots" of three independent experiments
Most MCF-7 cells died within 24 hours, while loss of membrane integrity was detected by 3 hours of treatment (FIG.
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SB). In FIG. SC, the live cell imaging experiment revealed
To demonstrate that the CT20 peptide could kill cancer
vacuolization, membrane fluctuations, and cell shrinkage of
cells in vivo, a small scale murine tumor experiment was
performed. MDA-MB-231 cells were implanted in the flanks
MDA-MB-231 cells following treatment with CT20 peptideof nude mice. Initial growth of tumors was detected after 2
nanoparticles. Within three hours, increased membrane rupturewas detected in MDA-MB-231 cellstreatedwithCOOH- 5 weeks. At this time tumors were measured, and over a 4-5 day
period, the mice were treated with intratumoral injections of
nanoparticles loaded with CT20 peptide (FIG. SD). These
results demonstrated that the CT20 peptide, once introduced
PBS, unloaded or empty nanoparticles (NP), or CT20 pepinto cells, rapidly triggered cell death. While the CT20 peptide/nanoparticles. The CT20 peptide prevented tumor
tide encapsulated in nanoparticles caused the death of four
growth as compared to empty nanoparticles or a PBS-treated
cancer cell lines (colon and breast), the CT20 Bax peptide/ 10 tumor. (FIG. 6C; results displayed in the graph show the
nanoparticle formulation was less effective inducing death in
change in tumor volume during the four days of treatment and
two lung cancer cell lines. This data indicated that that difare a representative of three independent experiments). These
ferences in the uptake and efficacy of the CT20 peptide/
results demonstrated that the CT20 peptide was effective not
nanoparticles could exist that are related to the physiology of
only in tissue culture, but also in the tumor environment.
the cancer cell.
15
Moreover, the ultrasound data in FIG. 6D showed little to
no observable damage of normal tissue surrounding the
5. The Death-Inducing Activity of the CT20p Peptide is
Independent ofCaspases and Resistant to Bcl-2.
regressing tumors treated with the CT20 peptide. FIG. 6D
To investigate the mechanism by which the CT20p peptide
provides representative ultrasound image of changes in tumor
was inducing cell death, MDA-MB-231 cells were treated
volume induced by treatment on days 0, 2 and 4 with the
with CT20 Bax peptide/nanoparticles (350 pM). A caspase 20 unloaded or CT20 peptide loaded nanoparticles. These findings indicate reduced uptake or effectiveness in non-cancerinhibitor (e.g., ZVAD-Fmk and/or CDDP) was added or
Bcl-2 was overexpressed. As shown in FIG. 6A, the CT20
ous cells.
peptide caused significant loss of membrane integrity, which
Collectively, these data demonstrated that the C-terminal
was largely unaffected by caspase inhibition with Z-VADdomain of Bax has membrane-binding capacity. The CT20p
FMK. In contrast, treatment of MDA-MB-231 cells with 25 peptide permeabilized membranes and caused cell death. The
cisplatin (CDDP) induced cell death that was inhibited by
CT20 peptide, unlike the full-length Bax protein, caused a
ZVAD-FMK. These results indicated that the death pathway
lethal cascade that resulted in membrane rupture that is not
induced by the CT20p peptide was different than CDDP and
characteristic of conventional apoptosis. The amphipathic
was independent of the effector caspases inhibited by ZVADfeatures of the CT20 peptide made it amenable to encapsulaFMK. When Bcl-2 was overexpressed, the overexpression 30 tion in nanoparticles and delivery to cancer cells. The CT20
did not impair the death activity of the CT20 Bax peptide, but
peptide caused the death of colon and breast cancer cells, even
rather slightly enhanced it. Bcl-2 overexpression impaired
in the absence of endogenous Bax or expression ofBcl-2, and
led to reduced tumor volume in a murine model. The CT20
death induced by CDDP (FIG. 6A). Administration of CD DP
peptide caused cell death in a manner that was different from
followed by treatment with the CT20 peptide was the most
effective in inducing cell death, which was not inhibited by 35 the apoptotic mechanism activated by CDDP.
Central to the lethal function of Bax is the membrane
ZVAD-FMK or Bcl-2 (FIG. 6A). The expression ofBcl-2 by
transfected cells was confirmed by immunoblotting lysates
binding capacity of domains like the C-terminal alpha-9
prepared from cells (FIG. 10).
helix. Loss of the C-terminus, or mutagenesis of Kl 89/Kl 90,
In FIG. 10, cells were transiently transfected with Bcl-2,
modulated the ability of Bax to associate with mitochondria.
treated with nanoparticles/CT20. Lysates were immunoblot- 40 The CT20 peptide, derived from the C-terminal a9 helix of
ted for Bcl-2. Controls are untransfected cells (UT) and
Bax, penetrated and permeabilized lipid vesicles. The CT20
Bax peptide, when encapsulated innanoparticles, was toxic at
untreated cells (control). * denotes a non-specific band. A
representative blot of two performed is shown.
picomolar concentrations. The CT20 Bax peptide/nanoparWhile Sytox is good indicator of cell death, it does not
ticle mixture induced morphological features of cell death
distinguish between apoptotic and necrotic cell death. There- 45 such loss of membrane integrity and cell shrinkage, but did
fore, to determine whether the CT20p peptide induced apopnot cause the changes in membrane symmetry that charactertotic cell death, the amount of membrane asymmetry caused
izes apoptosis. Use of the Bax CT20 peptide/nanoparticles as
by flipping of phospholipids in the plasma membrane using a
an anti-cancer agent was demonstrated when breast cancer
violet ratiometric probe was determined. In FIG. 6B, dot blots
cell lines succumbed to treatment as indicated by increased
show the comparison of loss of membrane integrity to 50 loss of membrane integrity that was not impaired by caspase
changes in membrane symmetry in MDA-MB-231 cells
inhibition or Bcl-2 expression. The CT20 peptide caused a
treated with CT20p peptide and/or CDDP. Treatment with the
form of cell death that was mechanistically different from
typical anti-cancer drugs like CDDP.
CT20p peptide encapsulated in nanoparticles enabled penThe data indicate that the CT20p peptide kills cells caused
etration of the DNA-binding dye (as shown in FIG. 6A), but
did not promote changes in membrane symmetry. This was 55 the formation of pores in mitochondrial membranes. The
minimally affected by caspase inhibition or Bcl-2 expression.
CT20p peptide was efficient at forming pores in zwitterionic
In contrast, contrast, CDDP induced significant alterations in
and anionic lipid membranes, leading to the release of calcein
the membrane symmetry detectable by the violet ratiometric
from loaded lipid vesicles. FIG. 11, for example, shows a
probe, which alterations were inhibited by ZVAD-FMK or
model for a membrane pore formed by the CT20 Bax peptide.
Bcl-2 (FIG. 6B; data shown is representative of more than 60 Control peptides did not permeabilize lipid membranes, causthree independent experiments). The combination treatment
ing calcein release, which indicated that the observed pore
of CDDP and CT20p peptide was the most efficacious and
formation was specific to the CT20 Bax peptide. Secondwas minimally affected by caspase inhibition or Bcl-2 expresorder rate kinetics revealed that initial pore formation by the
sion (FIG. 6B). These findings indicate that the CT20 peptide
CT20p peptide was slow, which was followed by a faster rate
engages in a death mechanism distinct from that of CDDP, 65 of assembly. The data indicate that the CT20p peptide formed
and that this distinct mechanism is independent of ZVDpores leading to membrane destabilization, ion exchange,
FMK inhibited-caspases and is resistant to Bcl-2.
and/or the release of sequestered molecules.
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Pore-forming proteins or peptides that can spontaneously
insert into lipid membranes and form stable pores have significant biological interest and clinical application. As demonstrated herein, the CT20 peptide, a shorter version of the a9
helix of Bax (amino acids 172-192), caused cell death indicated by membrane rupture. These findings indicate that the
CT20 peptide may cause necrotic-like cell death, rather than
conventional apoptosis, and therefore has the potential for
additive effects in combinatorial therapies with agents like
CDDP that induce apoptosis. The data presented herein show
that a small amount of the CT20 peptide was lethal under
conditions when the apoptotic machinery is intact (such as
Bax-containing HCT-116 cells) or when the apoptosis
machinery is defective (such as Bax deficient HCT-116 cells).
The CT20 peptide was also effective under conditions of
effector caspase inhibition or Bcl-2 over expression. These
data indicate that the CT20 peptide may be a potent killing
tool in cancers with abnormal levels of anti-apoptotic proteins, as well as cancers in which other survival signaling
mechanism may be irregular. FIG. 12, for example, shows a
hypothetical cell death pathway for CT20p peptide using a
basic model of apoptotic and non-apoptotic cell death.

normal, by 30-60 degrees. The tryptophan residue embed into
zwitterionic membranes at 8-9 A from membrane center.
Membrane anionic charge causes a deeper insertion oftryptophan for BaxC-KK and BaxC-LL but not BaxC-EE. Combined with pore stoichiometry, these data suggest a pore
model where eight peptide molecules form an "a/~-ring"
structure with pore inner diameter of 20-22 A. These results
identified a strong membranotropic activity of Bax C-terminus and proposed a new mechanism by which peptides can
efficiently perforate cell membranes and thus be used as cytotoxic agents.
Additionally, membrane insertion of the peptide and subsequent pore formation was mediated mainly by hydrophobic
rather than electrostatic interactions. In the presence of bulk
water, the peptides assume an a/~-type structure, with the
~-strands and a-helices significantly tilted relative to the
membrane normal. Altogether, the data are consistent with an
octameric "a/~-ring" structure with an internal pore diameter
ofat least 13 A to 20-22 A that caneffectivelytransfercalcein
and larger molecules. The data establish a foundation for
characterization of the molecular structure of the a/~ ring
transmembrane pore formed by Bax-derived peptides.
Example of Killing Microbial Cells
FIG. 13 shows a comparison ofCT20p peptide with antimicrobial peptides and apoptosis-inducing peptides.
Attributes are shared among the peptides. FIG. 14 shows that
Ct20p peptide inhibited the growth of E. coli, a gam negative
bacteria, in a dose dependent manner, inhibiting 50% of the
growth of bacteria at a dose of 50 µg. The inhibition of growth
began around 3 hours and reached a plateau at 13 hours, see
graph. These results compared to control peptide XL or no
peptide, in which growth began at 3 hours and plateaued at
6-7 hours. TheE. coli were grown in the presence ofa peptide,
concentrations ofCT20p peptide or for control, SCR peptide,
or no peptide for a control, in standard conditions for growing
bacteria in broth media.
FIG. 15 shows counts of the bacterial colonies from the
broth culture of FIG. 14. The bacterial culture media was
plated after 24 hours of treatment/exposure to Ct20p or the
control conditions, a peptide (SCR) or no peptide and addition of DMSO, and the resulting colonies were counted.
There were few bacterial colonies detected with CT20p treatment of 24 hours, which indicated that the effects of CT20p
peptide were bactericidal, not bacteriostatic (inhibition of
growth). A conclusion was that the inhibition of growth seen
in FIG. 14 was due to the killing or lysing of bacteria.
All of the compositions and/or methods disclosed and
claimed herein can be made and executed without undue
experimentation in light of the present disclosure. It will be
apparent to those skilled in the art that various modifications
and variations can be made in the present invention without
departing from the scope or spirit of the invention.
More specifically, certain agents which are both chemically and physiologically related can be substituted for the
agents described herein while the same or similar results can
be achieved. All such similar substitutes and modifications
apparent to those skilled in the art are deemed to be within the
spirit, scope and concept of the invention as defined by the
appended claims.
Other embodiments of the invention will be apparent to
those skilled in the art from consideration of the specification
and practice of the invention disclosed herein. It is intended
that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being
indicated by the following claims.
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Pore Formation by CT20p Peptide
An analysis of formation of relatively large membrane
pores by Bax C-terminal 20-reside peptide (CT20p) and two
mutants where the two native lysines are replaced either with
glutamates (charge reversal mutation) or leucines (charge
neutralization mutation) were examined. The three peptides
demonstrate distinct potencies to form pores in both zwitterionic and anionic membranes that transport calcein
(Mr-623). The most efficient pores are formed by the wildtype peptide in anionic membranes. The kinetics of calcein
release at various concentrations of the three peptides allowed
identification of the second-order rate constants of pore formation within the membrane, the affinity constants of peptide
units composing the pore, and the oligomeric pore structure.
Nucleation of the pore is shown to be relatively slow and
involve 2-3 peptide molecules, followed by a faster process of
assembly of the pore that includes up to eight peptide molecules. Structural studies led to a model of an octameric
transmembrane pore with an inner diameter of 20-22 A.
Analysis of the kinetics of calcein release from lipid vesicles
allows determination of rate constants of pore formation,
peptide-peptide affinities within the membrane, the oligomeric state oftransmembrane pores, and the role of the lysine
residues.
In summary, the C-terminal 20-residue stretch of Bax has
the capability of forming relatively large membrane pores
with a radius of at least 13 A. Replacement of the two lysine
residues close to the C-terminus with anionic glutamate or
nonpolar leucine residues reduce the pore forming activity of
the peptide, but the mutant peptides are still quite capable
pore formers. In general, the pore formation is a two-stage
process, nucleation and assembly of the final pore structure
that includes up to eight peptide molecules, and is stabilized
by intermolecular interaction energies of -10 to -13 kcal/
mo!, which is quite significant for 20-mer peptides.
Additionally, the pore structure was analyzed by polarized
Fourier transform infrared, circular dichroism, and fluorescence experiments on the peptides reconstituted in phospholipid membranes. The peptides assumed an a/~-type secondary structure within membranes. Both ~-strands and
a-helices are significantly tilted relative to the membrane
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TABLE 1
SE UENCES
Seq ID No. Description

Sequence

1

CT20Bax WT

VTIFVAGVLTASLTIWKKMG

2

CT20Bax EE

VTIFVAGVLTASLTIWEEMG

3

CT20Bax LL

VTIFVAGVLTASLTIWLLMG

4

CT20Bax RR

VTIFVAGVLTASLTIWRRMG

5

BAX-KK (for)

5'-GGATCACTCTCGGCCTGGACACCATGGG
GATGTACCCATACGATGTTCCAG
ATTACGCTGACGGGTCCGGGGAGCAG-3'

BAX-KK (rev)

5'-CGTCGACTGCAGAATTCTCAGCCCATC
TTCTTCCAGATGGTGAGCGAGG-3'

7

BAX-LlliT (1-19)
(for)

5'-CCGGGGAGCAGCCCCATATGTACCCAT
ACGATGTTCCAGATTACGCTATGAAG
ACAGGGGCCCTTTTGC-3'

8

BAX-LlliT (1-19)
(rev)

5'-CGTCGACTGCAGAATTCTCAGCCCATCTT
CTTCCAGATGGTGAGCGAGG-3'
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TABLE 1-continued
SE UENCES
Seq ID No. Description

Sequence

9

BAX-LI.CT (1 73192) (for)

5'-GGATCACTCTCGGCCTGGACACCATGG
GGATGTACCCATACGATGTTCCAG
ATTACGCTGACGGGTCCGGGGAGCAG-3'

10

BAX-LI.CT (1 73192) (rev)

5'-CGTCGACTGCAGAATTCTCAGGTCTGCCA
CGTGGGCGTCCAAAG-3'

11

BAX-LL (for)

5'-GGATCACTCTCGGCCTGGACACCATGG
GGATGTACC CATACGA TGTTCCAG
ATTACGCTGACGGGTCCGGGGAGCAG-3'

12

BAX-LL (rev)

5'-CGTCGACTGCAGAATTCTCAGCCCATGA
GGAGCCAGATGGTGAGCGAGG-3'

13

BAX-DD (for)

5'-GGATCACTCTCGGCCTGGACACCATG
GGGATGTACCCATACGATGTTCCAG
ATTACGCTGACGGGTCCGGGGAGCAG-3'

14

BAX-DD (rev)

5'-CGTCGACTGCAGAATTCTC
AGCCCATGTCGTCCCAGATGGTGAGCGAGG-3'

15

BAX-EE (for)

5'-GGATCACTCTCGGCCTGGACACCATGGG
GATGTACCCATACGATGTTCCAG
ATTACGCTGACGGGTCCGGGGAGCAG-3'

16

BAX-EE (rev)

5'-CGTCGACTGCAGAATTCTCAGCCC
ATCTCCTCCCAGATGGTGAGCGAGG-3'

17

BAX-RR (for)

5'-GGATCACTCTCGGCCTGGACACCATG
GGGATGTACCCATACGATGTTCCAG
ATTACGCTGACGGGTCCGGGGAGCAG-3'

18

BAX-RR (rev)

5'-CGTCGATCTCAGCCCATTCGTCGCC
ACATGGTGAGCGAGG-3'

19

BAX-QQ (for)

5'-GGATCACTCTCGGCCTGGACACCAT
GGGGATGTACCCATACGATGTTCCAG
ATTACGCTGACGGGTCCGGGGAGCAG-3'

20

BAX-QQ (rev)

5'-CGTCGACTGCAGAATTC TCAGCCCATC
TGCTGCCAGATGGTGAGCGAGG-3'

21

BAX-KMGK
(for)

5'-GGATCACTCTCGGCCTGGACACCATG
GGGATGTACCCATACGATGTTCCAG
ATTACGCTGACGGGTCCGGGGAGCAG -3'

22

BAX-KMGK
(rev)

5'-CGTCGACTGCAGAATTCTCACTTCCCCA
TCTTCCAGATGGTG AGCGAGG-3'

23

BAX-EK (for)

5'-GGATCACTCTCGGCCTGGACACCATG
GGGATGTACCCATACGATGTTCCAG
ATTACGCTGACGGGTCCGGGGAGCAG-3'

24

BAX-EK (rev)

5'-CGTCGACTGCAGAATTCTCAGCCCA
TCTTCTCCCAGATGGTGAGCGAGG-3'

25

GFP-CT-WT (for)

5'-GGATCACTCTCGGCCTGGACGA
GGATATCATGGTGAGCAAG-3'

26

GFP-CT-WT (rev)

5'-CGTCGACTGCAGATATCTCAGCCCA
TCTTCTTC CAGATGGTGAGCGAGG
CGGTGAGCACTCCCGCCACAAAGATG
GTCACGGTGTTATCTAGATC-3'

27

GFP-CT-EE (for)

5'-GGATCACTCTCGGCCTGGACGA
GGATATCATGGTGAGCAAG-3'

28

GFP-CT-EE (rev)

5'-CGTCGACTGCAGATATCTCAGCCCATC
TCCTCC CAGATGGTGAGCGAGGC
GGTGAGCACTCCCGCCACAAAGATGG
TCACGGTGTTATCTAGATC-3'

29

GFP-CT-RR (for)

5'-GGATCACTCTCGGCCTGGACGA
GGATATCATGGTGAGCAAG-3'
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TABLE 1-continued
SE UENCES
Seq ID No. Description

Sequence

30

GFP-CT-RR (rev)

5'-CGTCGACTGCAGATATCTCAGCCCATG
AGGAGC CAGATGGTGAGCGAGGCGGTG
AGCACTCCCGCCACAAAGATGG
TCACGGTGTTATCTAGATC-3'

31

DD-CT-WT (for)

5'-AATTCTGTGACCATCTTTGTGGCGGGA
GTGCTCACCGCCTCGCTCACCATC
TGGAAGAAGATGGGCTGA-3'

32

DD-CT-WT (rev)

5'-GATCTCAGCCCATCTTCTTCCAGATGG
TGAGCGAGGCGGTGAGCACTCCCG
CCACAAAGATGGTCACAG-3'

33

DD-CT-EE (for)

5'-AATTCTGTGACCATCTTTGTGGC
GGGAGTGCTCACCGCCTCGCTCACCA
TCTGGGAGGAGATGGGCTGA-3'

34

DD-CT-EE (rev)

5'-GATCTCAGCCCATCTCCTCCCAGA
TGGTGAGCGAGGCGGTGAGCA
CTCCCGCCACAAA GATGGTCACAG-3'

35

DD-CT-LL (for)

5'-AATTCTGTGACCATCTTTGTGGCGGGA
GTGCTCACCGCCTCGCTCACCATCTGGC
TCCTCATGGGCTGA-3'

36

DD-CT-LL (rev)

5'-GATCTCAGCCCATGAGGAGCCAGA
TGGTGAGCGAGGCGGTGA
GCACTCCCGCCACAAA GATGGTCACAG-3'

37

DD-CT-RR (for)

5'-AATTCTGTGACCATCTTTGTGGCGGGA
GTGCTCACCGCCTCGCTCAC
CATCTGGCGACGAATGGGCTGA-3'

38

DD-CT-RR (rev)

5-GATCTCAGCCCATTCGTCGCCAGA
TGGTGAGCGAGGCGGTGAGCAC
TCCCGCCACAAA GATGGTCACAG-3'

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS,
<210>
<211>
<212>
<213>

64

SEQ ID NO 1
LENGTH, 20
TYPE, PRT
ORGANISM, Homo sapiens

<400> SEQUENCE,

1

Val Thr Ile Phe Val Ala Gly Val Leu Thr Ala Ser Leu Thr Ile Trp
1
5
10
15
Lys Lys Met Gly
20

<210>
<211>
<212>
<213>
<220>

SEQ ID NO 2
LENGTH, 20
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,

<223> OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 2
Val Thr Ile Phe Val Ala Gly Val Leu Thr Ala Ser Leu Thr Ile Trp
1
5
10
15
Glu Glu Met Gly
20
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50

49
-continued
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 3
LENGTH, 20
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 3
Val Thr Ile Phe Val Ala Gly Val Leu Thr Ala Ser Leu Thr Ile Trp
1
5
10
15
Leu Leu Met Gly
20

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 4
LENGTH, 20
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 4
Val Thr Ile Phe Val Ala Gly Val Leu Thr Ala Ser Leu Thr Ile Trp
1
5
10
15
Arg Arg Met Gly
20

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 5
LENGTH, 77
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 5
ggatcactct cggcctggac accatgggga tgtacccata cgatgttcca gattacgctg

60

acgggtccgg ggagcag

77

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 6
LENGTH, 49
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE,
cgtcgactgc agaattctca gcccatcttc ttccagatgg tgagcgagg

<210>
<211>
<212>
<213>
<220>
<223>

49

SEQ ID NO 7
LENGTH, 69
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 7
ccggggagca gccccatatg tacccatacg atgttccaga ttacgctatg aagacagggg

60

cccttttgc

69

<210> SEQ ID NO 8
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52
-continued

<211>
<212>
<213>
<220>
<223>

LENGTH, 49
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 8
cgtcgactgc agaattctca gcccatcttc ttccagatgg tgagcgagg

<210>
<211>
<212>
<213>
<220>
<223>

49

SEQ ID NO 9
LENGTH, 77
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 9
ggatcactct cggcctggac accatgggga tgtacccata cgatgttcca gattacgctg

60

acgggtccgg ggagcag

77

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 10
LENGTH, 44
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 10
cgtcgactgc agaattctca ggtctgccac gtgggcgtcc aaag

<210>
<211>
<212>
<213>
<220>
<223>

44

SEQ ID NO 11
LENGTH, 77
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 11
ggatcactct cggcctggac accatgggga tgtacccata cgatgttcca gattacgctg

60

acgggtccgg ggagcag

77

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 12
LENGTH, 49
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 12
cgtcgactgc agaattctca gcccatgagg agccagatgg tgagcgagg

<210>
<211>
<212>
<213>
<220>
<223>

49

SEQ ID NO 13
LENGTH, 77
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 13
ggatcactct cggcctggac accatgggga tgtacccata cgatgttcca gattacgctg

60
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53
-continued
acgggtccgg ggagcag

<210>
<211>
<212>
<213>
<220>
<223>

77

SEQ ID NO 14
LENGTH, 49
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 14
cgtcgactgc agaattctca gcccatgtcg tcccagatgg tgagcgagg

<210>
<211>
<212>
<213>
<220>
<223>

49

SEQ ID NO 15
LENGTH, 77
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 15
ggatcactct cggcctggac accatgggga tgtacccata cgatgttcca gattacgctg

60

acgggtccgg ggagcag

77

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 16
LENGTH, 49
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 16
cgtcgactgc agaattctca gcccatctcc tcccagatgg tgagcgagg

<210>
<211>
<212>
<213>
<220>
<223>

49

SEQ ID NO 17
LENGTH, 77
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 17
ggatcactct cggcctggac accatgggga tgtacccata cgatgttcca gattacgctg

60

acgggtccgg ggagcag

77

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 18
LENGTH, 40
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 18
cgtcgatctc agcccattcg tcgccacatg gtgagcgagg

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 19
LENGTH, 77
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note

40
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56
-continued

synthetic construct

<400> SEQUENCE, 19
ggatcactct cggcctggac accatgggga tgtacccata cgatgttcca gattacgctg

60

acgggtccgg ggagcag

77

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 20
LENGTH, 49
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 20
cgtcgactgc agaattctca gcccatctgc tgccagatgg tgagcgagg

<210>
<211>
<212>
<213>
<220>
<223>

49

SEQ ID NO 21
LENGTH, 77
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 21
ggatcactct cggcctggac accatgggga tgtacccata cgatgttcca gattacgctg

60

acgggtccgg ggagcag

77

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 22
LENGTH, 49
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 22
cgtcgactgc agaattctca cttccccatc ttccagatgg tgagcgagg

<210>
<211>
<212>
<213>
<220>
<223>

49

SEQ ID NO 23
LENGTH, 77
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 23
ggatcactct cggcctggac accatgggga tgtacccata cgatgttcca gattacgctg

60

acgggtccgg ggagcag

77

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 24
LENGTH, 49
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 24
cgtcgactgc agaattctca gcccatcttc tcccagatgg tgagcgagg

<210> SEQ ID NO 25

49
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57
-continued
<211>
<212>
<213>
<220>
<223>

LENGTH, 41
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 25
ggatcactct cggcctggac gaggatatca tggtgagcaa g

<210>
<211>
<212>
<213>
<220>
<223>

41

SEQ ID NO 26
LENGTH, 95
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 26
cgtcgactgc agatatctca gcccatcttc ttccagatgg tgagcgaggc ggtgagcact

60

cccgccacaa agatggtcac ggtgttatct agate

95

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 27
LENGTH, 41
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 27
ggatcactct cggcctggac gaggatatca tggtgagcaa g

<210>
<211>
<212>
<213>
<220>
<223>

41

SEQ ID NO 28
LENGTH, 95
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 28
cgtcgactgc agatatctca gcccatctcc tcccagatgg tgagcgaggc ggtgagcact

60

cccgccacaa agatggtcac ggtgttatct agate

95

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 29
LENGTH, 41
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 29
ggatcactct cggcctggac gaggatatca tggtgagcaa g

<210>
<211>
<212>
<213>
<220>
<223>

41

SEQ ID NO 30
LENGTH, 95
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 30
cgtcgactgc agatatctca gcccatgagg agccagatgg tgagcgaggc ggtgagcact

60
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59
-continued
cccgccacaa agatggtcac ggtgttatct agate

<210>
<211>
<212>
<213>
<220>
<223>

95

SEQ ID NO 31
LENGTH, 69
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 31
aattctgtga ccatctttgt ggcgggagtg ctcaccgcct cgctcaccat ctggaagaag

60

atgggctga

69

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 32
LENGTH, 69
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 32
gatctcagcc catcttcttc cagatggtga gcgaggcggt gagcactccc gccacaaaga

60

tggtcacag

69

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 33
LENGTH, 69
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 33
aattctgtga ccatctttgt ggcgggagtg ctcaccgcct cgctcaccat ctgggaggag

60

atgggctga

69

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 34
LENGTH, 69
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 34
gatctcagcc catctcctcc cagatggtga gcgaggcggt gagcactccc gccacaaaga

60

tggtcacag

69

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 35
LENGTH, 69
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 35
aattctgtga ccatctttgt ggcgggagtg ctcaccgcct cgctcaccat ctggctcctc

60

atgggctga

69
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62
-continued

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 36
LENGTH, 69
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 36
gatctcagcc catgaggagc cagatggtga gcgaggcggt gagcactccc gccacaaaga

60

tggtcacag

69

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 37
LENGTH, 69
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 37
aattctgtga ccatctttgt ggcgggagtg ctcaccgcct cgctcaccat ctggcgacga

60

atgggctga

69

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 38
LENGTH, 69
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Description of artificial sequence note
synthetic construct

<400> SEQUENCE, 38
gatctcagcc cattcgtcgc cagatggtga gcgaggcggt gagcactccc gccacaaaga

60

tggtcacag

69

<210>
<211>
<212>
<213>

SEQ ID NO 39
LENGTH, 25
TYPE, PRT
ORGANISM, Bos taurus

<400> SEQUENCE, 39
Phe Lys Cys Arg Arg Trp Gln Trp Arg Met Lys Lys Leu Gly Ala Pro
1
5
10
15
Ser Ile Thr Cys Val Arg Arg Ala Phe
20
25

<210>
<211>
<212>
<213>

SEQ ID NO 40
LENGTH, 13
TYPE, PRT
ORGANISM, Bos taurus

<400> SEQUENCE, 40
Ile Leu Pro Trp Lys Trp Pro Trp Trp Pro Trp Arg Arg
1
5
10

<210>
<211>
<212>
<213>

SEQ ID NO 41
LENGTH, 26
TYPE, PRT
ORGANISM, Apis mellifera

<400> SEQUENCE, 41
Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu
1
5
10
15
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63
-continued
Ile Ser Trp Ile Lys Arg Lys Arg Gln Gln
20
25

<210>
<211>
<212>
<213>

SEQ ID NO 42
LENGTH, 24
TYPE, PRT
ORGANISM, Rana acanthi

<400> SEQUENCE,

42

Phe Leu Pro Val Leu Ala Gly Ile Ala Ala Lys Val Val Pro Ala Leu
1
5
10
15
Phe Cys Lys Ile Thr Lys Lys Cys
20

<210>
<211>
<212>
<213>

SEQ ID NO 43
LENGTH, 20
TYPE, PRT
ORGANISM, Rana acanthi

<400> SEQUENCE,

43

Phe Leu Gly Gly Leu Ile Lys Ile Val Pro Ala Met Ile Cys Ala Val
1
5
10
15
Thr Lys Lys Cys
20

<210>
<211>
<212>
<213>

SEQ ID NO 44
LENGTH, 37
TYPE, PRT
ORGANISM, Trigoniopthalmus alternatus

<400> SEQUENCE,

44

Lys Trp Lys Leu Phe Lys Lys Ile Glu Lys Val Gly Gln Asn Ile Arg
1
5
10
15
Asp Gly Ile Ile Lys Ala Gly Pro Ala Val Ala Val Val Gly Gln Ala
20
25
30
Thr Gln Ile Ala Lys
35

<210>
<211>
<212>
<213>

SEQ ID NO 45
LENGTH, 34
TYPE, PRT
ORGANISM, Rana acanthi

<400> SEQUENCE,

45

Ala Leu Trp Lys Thr Met Leu Lys Lys Leu Gly Thr Met Ala Leu His
1
5
10
15
Ala Gly Lys Ala Ala Leu Gly Ala Ala Ala Asp Thr Ile Ser Gln Gly
20
25
30
Thr Gln

<210>
<211>
<212>
<213>

SEQ ID NO 46
LENGTH, 23
TYPE, PRT
ORGANISM, Rana acanthi

<400> SEQUENCE,

46

Gly Ile Gly Lys Phe Leu His Ser Ala Lys Lys Phe Gly Lys Ala Phe
1
5
10
15
Val Gly Glu Ile Met Asn Ser
20
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65

66
-continued

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 47
LENGTH, 20
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, synthetic construct; CT20p REV peptide

<400> SEQUENCE, 47
Gly Met Lys Lys Trp Ile Thr Leu Ser Ala Thr Leu Val Gly Ala Val
1
5
10
15
Phe Thr Ile Val
20

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 48
LENGTH, 14
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, synthetic construct; KLA peptide

<400> SEQUENCE, 48
Lys Leu Ala Lys Leu Ala Lys Lys Leu Ala Lys Leu Ala Lys
1
5
10

<210>
<211>
<212>
<213>

SEQ ID NO 49
LENGTH, 29
TYPE, PRT
ORGANISM, Homo sapiens

<400> SEQUENCE, 49
Asp Gly Asn Phe Asn Trp Gly Arg Val Val Ala Leu Phe Tyr Phe Ala
1
5
10
15
Ser Lys Leu Val Leu Lys Val Pro Glu Leu Ile Arg Thr
20
25

<210>
<211>
<212>
<213>

SEQ ID NO 50
LENGTH, 20
TYPE, PRT
ORGANISM, Homo sapiens

<400> SEQUENCE, 50
Met Arg Pro Glu Ile Trp Ile Ala Gln Glu Leu Arg Arg Ile Gly Asp
1
5
10
15
Glu Phe Asn Ala
20

<210>
<211>
<212>
<213>

SEQ ID NO 51
LENGTH, 20
TYPE, PRT
ORGANISM, Homo sapiens

<400> SEQUENCE, 51
Glu Asp Ile Ile Arg Asn Ile Ala Arg His Leu Ala Gln Val Gly Asp
1
5
10
15
Ser Met Asp Arg
20

<210>
<211>
<212>
<213>

SEQ ID NO 52
LENGTH, 16
TYPE, PRT
ORGANISM, Homo sapiens

<400> SEQUENCE, 52
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67
-continued
Gly Gln Val Gly Arg Gln Leu Ala Ile Ile Gly Asp Asp Ile Asn Arg
1
5
10
15

<210>
<211>
<212>
<213>
<220>
<223>
<220>
<221>
<222>
<223>

SEQ ID NO 53
LENGTH, 20
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, synthetic construct; CT20p peptide
FEATURE,
NAME/KEY, MOD_RES
LOCATION, (1) .. (1)
OTHER INFORMATION, ACETYLATION

<400> SEQUENCE, 53
Val Ile Thr Phe Val Ala Gly Val Leu Thr Ala Ser Leu Thr Ile Trp
1
5
10
15
Lys Lys Met Gly
20

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 54
LENGTH, 4
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, synthetic construct; Bax intracellular
localization peptide

<400> SEQUENCE, 54
Lys Lys Met Gly
1

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 55
LENGTH, 4
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, synthetic construct; mutant Bax intracellular
localization peptide

<400> SEQUENCE, 55
Leu Lys Met Gly
1

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 56
LENGTH, 4
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, synthetic construct; mutant Bax intracellular
localization peptide

<400> SEQUENCE, 56
Lys Leu Met Gly
1

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 57
LENGTH, 4
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, synthetic construct; mutant Bax intracellular
localization peptide

<400> SEQUENCE, 57
Leu Leu Met Gly
1
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69

70
-continued

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 58
LENGTH, 4
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, synthetic construct; mutant Bax intracellular
localization peptide

<400> SEQUENCE, 58
Glu Lys Met Gly
1

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 59
LENGTH, 4
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, synthetic construct; mutant Bax intracellular
localization peptide

<400> SEQUENCE, 59
Lys Glu Met Lys
1

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 60
LENGTH, 4
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, synthetic construct; mutant Bax intracellular
localization peptide

<400> SEQUENCE, 60
Glu Glu Met Gly
1

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 61
LENGTH, 4
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, synthetic construct; mutant Bax intracellular
localization peptide

<400> SEQUENCE, 61
Gln Gln Met Gly
1

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 62
LENGTH, 4
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, synthetic construct; mutant Bax intracellular
localization peptide

<400> SEQUENCE, 62
Asp Asp Met Gly
1

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 63
LENGTH, 4
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, synthetic construct; mutant Bax intracellular
localization peptide

US 9,040,662 B2
72

71
-continued
<400> SEQUENCE, 63
Arg Arg Met Gly
1

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 64
LENGTH, 4
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, synthetic construct; mutant Bax intracellular
localization peptide

<400> SEQUENCE, 64
Lys Met Gly Lys
1

What is claimed is:
8. The method of claim 7, wherein the nanoparticles are
20
aminated.
1. A method of permeabilizing membranes of cells, com9. The method of claim 7, wherein the nanoparticles are
prising, administering to the cell an effective amount of a) a
carboxylated.
C-terminal B cell lymphoma-2 (Bcl-2)-associated X protein
10. The method of claim 1, further comprising administer(Bax) peptide (CT20p peptide), wherein the CT20p peptide
comprises SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, 25 ing to the cell one or more therapeutic agents.
11. The method of claim 1, wherein the cell is a cancer cell.
or a combination of two or more of SEQ ID NOs: 1-4, orb) a
12. The method of claim 11, wherein the cancer cell is a
composition comprising a CT20p peptide, wherein the combreast cancer cell, colorectal cancer cell, or lung cancer cell,
position comprises SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID
or wherein the cancer cell is a drug resistant cancer cell.
NO: 4, or a combination of two or more of SEQ ID NOs: 1-4.
13. The method of claim 1, wherein the membrane is a
2. The method of claim 1, further comprising repeating the 30
mitochondrial membrane.
administration of the CT20p peptide or the composition com14. A composition for permeabilizing membranes in cells,
prising the CT20p peptide.
comprising, a CT20p peptide, wherein the CT20p peptide
3. The method of claim 1, comprising administering the
comprises SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4,
CT20p peptide or CT20p peptide composition directly into a
or
a combination of two or more of SEQ ID NOs: 1-4.
tumor cell.
35
15. The composition of claim 14, wherein the CT20p pep4. The method of claim 1, further comprising inducing cell
tide is encapsulated in polymeric nanoparticles.
death.
16. The composition of claim 15, wherein the nanopar5. The method of claim 4, wherein the cell death occurs
ticles
are aminated.
independently of endogenous Bax activity, or endogenous
17. The composition of claim 15, wherein the nanoparcaspase activity, or both.
40
ticles are carboxylated.
6. The method of claim 4, wherein the cell death is resistant
18. The composition of claim 14, further comprising one or
to B cell lymphoma-2 (Bcl-2) over-expression.
more
therapeutic agents.
7. The method of claim 1, wherein the CT20p peptide is
encapsulated in polymeric nanoparticles.
* * * * *

